Cancer vaccines containing xenogeneic epitopes of telomerase reverse transcriptase

ABSTRACT

It has been discovered that a robust and therapeutic anti-cancer response can be generated by immunizing with a xenogeneic form of the enzyme telomerase reverse transcriptase (TERT). Cancer subjects are multiply immunized with TERT from another species—either in protein form, or with a TERT expression vector. Presence of the xenogeneic components apparently overcomes natural immunotolerance to self-antigen. The response can be focused by simultaneous or subsequent immunization with isogenic TERT. As a result, the immune system generates T lymphocytes that are cytotoxic for virtually any cancer cell, by virtue of TERT expressed due to malignant transformation. The anti-tumor response causes a substantial inhibition of tumor cell growth, demonstrating the therapeutic benefit of this invention.

REFERENCE TO RELATED APPLICATIONS

[0001] This disclosure claims the priority benefit of U.S. provisional application 60/393,295, filed Jun. 27, 2002. The priority application is hereby incorporated herein by reference in its entirety.

TECHNICAL FIELD

[0002] This invention relates to the field of immunization strategies for the treatment of cancer. The invention overcomes tolerance to telomerase reverse transcriptase, a self-antigen expressed by cancer cells, generating a therapeutically beneficial anti-telomerase specific immune response.

BACKGROUND

[0003] Telomere dynamics and telomerase expression are fundamentally involved in cellular aging and cancer. Activation of the genes for the telomerase complex is associated with cell immortality and human malignancies. Kim et al. (Science 266:2011, 1994) described the specific association of human telomerase activity with cancer cells. It has been proposed that cell immortalization is required for long-term growth of the vast majority of malignant or metastatic tumors, and that advances in telomere biology and telomerase inhibition will improve the way cancers are diagnosed and treated (Harley et al., Important Adv. Oncol. 57, 1996).

[0004] U.S. Pat. No. 5,583,016 describes the cloning and characterization of the RNA component of human telomerase. U.S. Pat. No. 6,300,110 describes the cloning and characterization of TPC2 and TPC3, two proteins that share with telomerase the property that expression levels increase in cancer cells. U.S. Pat. Nos. 6,517,834 and 6,545,133 describe the isolation of the human telomerase holoenzyme by affinity techniques. U.S. Pat. Nos. 6,166,178, and 6,261,836, and Nakamura et al. (Science 277:955, 1997) describe the cloning and characterization of the telomerase catalytic subunit, and its use to make anti-telomerase antibody.

[0005] U.S. Pat. No. 6,440,735 describes dendritic cell vaccines containing telomerase reverse transcriptase (TERT) for the treatment of cancer. The antigen-presenting cells contain or are transfected to express a portion of TERT. When the cellular composition is administered to human subjects such as cancer patients, it induces an anti-TERT immunological response. Dendritic cells primed in this way can also be used to stimulate cytotoxic T cells that are specific for TERT. As of the time of the filing of this application, a vaccine comprising dendritic cells pulsed with TERT mRNA was in Phase 1 clinical trials at the Duke University Medical Center. The data suggest the vaccine was very well tolerated, and resulted in the generation of an anti-telomerase immune response in almost all patients (Geron Press Release, Apr. 7, 2003).

[0006] These results are encouraging. However, it is not always convenient to prepare a dendritic cell composition from patients diagnosed with cancer. The present invention provides an alternative strategy for overcoming self-tolerance, thereby eliciting an anti-telomerase cytotoxic T cell response, which then helps eradicate the tumor.

SUMMARY

[0007] This invention provides a system for eliciting an immune response in a mammalian subject that is specific for its own telomerase reverse transcriptase (TERT). In a typical embodiment, the subject is administered with an immunogenic composition containing part of a homolog TERT, either in protein form or encoded in a nucleic acid. In some instances, one or more homologs are administered in combination with simultaneous or sequential administration of isogenic TERT.

[0008] Ideal homologs are full-length TERT and TERT fragments of various lengths of species xenogeneic to the subject being treated—particularly mammals and other eukaryotes. Also suitable are naturally occurring TERT sequences modified with one or more amino acid changes introduced for any reason, such as to eliminate telomerase activity. Also suitable are artificial sequences that mimic TERT epitopes, such as optimized and consensus sequences.

[0009] Medicinal compositions of this invention can be formulated for clinical treatment of humans or other animals, or for research purposes. The TERT compositions of this invention are often administered to the subject several times: first to initiate the response, and then to potentiate or focus the effect. Desirable outcomes are to elicit or enhance an immunological response (such as a cytotoxic T cell response) against TERT or against the subject's cancer, and production of mediators like IL-8 that directly or indirectly influence cancer cell apoptosis or elimination. These events alone or in combination can result in modulation of tumor growth, and stabilization or improvement of the clinical condition.

[0010] Embodiments of this system include therapeutic compositions and combinations (packaged or distributed separately or together), methods for producing and testing such compositions, and the use of such compositions for preparing medicine and treating telomerase-associated disease.

[0011] Other aspects of the invention relate to novel and modified forms of TERT and the genes that encode them. This disclosure provides the first sequence data for dog TERT, and for consensus and variant forms of TERT. These embodiments have utility for research, diagnostic, and therapeutic applications, as exemplified below.

[0012] Additional aspects of the invention will be apparent from the description that follows.

DRAWINGS

[0013]FIG. 1 shows that vaccination of tumor-bearing mice with dendritic cells (DCs) primed with adenovirus expression vector for human telomerase reverse transcriptase (hTERT) is more effective than mouse TERT (mTERT) in halting tumor growth.

[0014]FIG. 2 shows that tumor rejection in these mice correlates with the presence of IFN-γ producing T lymphocytes that are specific for TERT.

[0015]FIG. 3 shows the results of experiments in which animals were immunized not with dendritic cells, but with TERT expression vectors. T lymphocytes from individual mice immunized with hTERT are cytotoxic for B16F10 mouse melanoma tumor cells (transduced with AdhTERT or unmodified), for B10.2 mouse tumor cells, and for C57 mouse fibrosarcoma cells. The target antigen meditating cytotoxicity is thought to be mTERT expressed endogenously by the mouse tumors.

[0016]FIG. 4 shows IFN-γ expression by T cells from two experiments in which mice were vaccinated according to the protocol shown on the abscissa. Specific CD positive cells predominate in mice immunized with xenogeneic hTERT.

[0017]FIG. 5 shows that xenogeneic antigen followed by self antigen is better than self antigen alone in generating specific cytotoxic T lymphocytes, and lymphocytes that specifically produce IFN-γ.

[0018]FIG. 6 is taken from an experiment in which mice were immunized four times with mTERT DNA, or twice each with hTERT DNA followed by mTERT DNA. The mice immunized with a combination of hTERT and mTERT had more mTERT-specific CTLs. The level of killing is higher in this experiment because the target cells had been transduced with AdmTERT. This confirms that the killing of the tumor cells is mediated by the TERT antigen.

[0019]FIG. 7 shows that immunizing with a combination of hTERT and mTERT leads to a specific CTL response against autologous antigen. The mice were immunized nine times with 100 μg DNA followed by electroporation. Splenocytes were harvested and stimulated with irradiated mTERT expressing cells. mTERT-specific killing (mean±SEM) was highest for animals multiply immunized with xenogeneic TERT, followed by isogenic TERT.

[0020]FIG. 8 shows that immunization with xenogeneic TERT effectively inhibits tumor growth. Mice were immunized three times with adenovirus hTERT virus expression vector or control vector. The animals immunized with xenogeneic hTERT (diamonds) resisted tumor growth by almost 3-fold, compared with vector control (p<0.05).

[0021]FIG. 9 is an alignment of TERT protein sequences from human (SEQ. ID NO:2), mouse (SEQ. ID NO:4), hamster (SEQ. ID NO:6), rat (SEQ. ID NO:8), and dog (SEQ. ID NO:10). Shown below is a consensus sequence (SEQ. ID NO:12).

[0022] FIG. 10 is an alignment of TERT encoding gene sequences from human (SEQ. ID NO:1), mouse (SEQ. ID NO:3), hamster (SEQ. ID NO:5), rat (SEQ. ID NO:7), and dog (SEQ. ID NO:9). Shown below is a consensus sequence (SEQ. ID NO:11).

DETAILED DESCRIPTION

[0023] Normally, the telomeres that form the aglet on the ends of chromosomes shorten a small amount after each cell division. This limits the replicative capacity of mammalian cells to 50-100 divisions, before they undergo replicative senescence.

[0024] Telomerase serves a key role in preventing replicative senescence in immortal cell lines by periodically restoring length to the telomeres. It is expressed by embryonic stem cells, which can be grown in culture indefinitely (WO 01/51616). It is also expressed in a transient fashion in adult cells with special replicative requirements, such as certain tissue-specific stem cells, and T lymphocytes during activation. However, most adult cells don't express telomerase reverse transcriptase (TERT, the catalytic component of the enzyme) unless they undergo malignant transformation.

[0025] The expression pattern of TERT makes it a good target for a cancer vaccine. However, since telomerase is a self-antigen, there is a formidable problem in overcoming the natural process of immune tolerance to self-antigens in order to summon an adequate immune response to have a serious impact on a growing tumor.

[0026] This disclosure overcomes the problem by demonstrating that cross-species epitopes can be used as a way of initiating an effective anti-TERT response for the treatment of cancer.

[0027] The discovery was made in part during the course of experiments in which mice were injected with expression vectors for autologous TERT. As a positive control, cohort mice were immunized with human TERT, which is over 30% different from mouse TERT and therefore should be quite immunogenic. When T cells were isolated form these mice, it was found that they could kill target cells transfected to express human TERT, as expected. Surprisingly, they were also found to kill target cells expressing mouse TERT—both in transfected cells, and from the endogenous mTERT gene expressed in mouse tumor cells. This demonstrates that immunization with cross-species epitopes overcomes tolerance to self-antigen, and elicits a response sufficiently cross-reactive that it mediates killing of tumor cells of the host species.

[0028] As a refinement to this technique, cross-species TERT epitopes can be used in conjunction with autologous TERT epitopes. The subject is immunized with cross-species epitopes to overcome self-tolerance and begin the generation of cross-reactive T cells specific for autologous TERT. Simultaneously or at a later time, the subject is also immunized with autologous TERT, which serves the function of focusing the response towards autologous epitopes, promoting maturation of the immune response in the direction of high-affinity reactivity against antigen expressed on tumor cells.

[0029] Use of this strategy to overcome tolerance and raise a response against syngeneic tumor cells is illustrated in the Example section appearing later in this disclosure. FIG. 1 shows that mice injected with dendritic cells expressing human TERT (or hTERT followed by mouse TERT) are better protected against tumor challenge than mice injected with mTERT alone. As it turns out, using cross-species epitopes to elicit a protective response does not require the presence of dendritic cells in the composition. FIG. 3 shows CTL activity against a variety of different mouse tumor cells in T cells obtained from mice immunized with hTERT. FIG. 4 shows that T cells with the CD8 (CTL) phenotype that express IFN-γ are specifically elicited in the mice immunized with hTERT. FIGS. 5 and 6 show that the combination of human and mouse TERT vaccination using a DNA expression vector is better than vaccination with mTERT DNA alone, and that the proportion of target cell killing depends on the amount of mTERT they express—confirming that mTERT is the antigen being recognized.

[0030]FIG. 7 shows that the strategy of immunizing first with cross-species TERT, and then with autologous TERT, provides higher levels of CTL killing than immunizing with either TERT alone. FIG. 8 demonstrates that the CTL response elicited by cross-species TERT is protective against syngeneic tumor cells.

[0031] Accordingly, it is now possible with an acellular vaccine composition comprising cross-species epitopes to generate a CTL response that provides a therapeutic benefit against cancer.

[0032] The strategy illustrated in these examples is readily adapted to human therapy by using a non-human TERT or portion thereof to provide the cross-reactive epitopes that overcome self-tolerance and initiate a response that cross-reacts with autologous TERT. Optionally, the patient is also treated with human TERT or a portion thereof to focus the response through affinity maturation towards the intended target on the tumor cells. Indeed, the mouse is a more rigorous test of the viability of this strategy because unlike in humans, TERT is endogenously expressed by most adult mouse cells. Thus, self-tolerance against TERT epitopes will be promoted more vigorously in the mouse on an ongoing basis. Adapting the strategy to human therapy brings it into a less tolerized host, generating CTLs against autologous TERT in a less stringent system.

[0033] General Techniques

[0034] For further elaboration of general techniques useful in the practice of this invention, the practitioner can refer to standard textbooks and reviews in cell and molecular biology, tissue culture, and veterinary and human medicine.

[0035] Reference books for molecular genetics and genetic engineering include the current editions of Molecular Cloning: A Laboratory Manual, (Sambrook et al., Cold Spring Harbor); Gene Transfer Vectors for Mammalian Cells (Miller & Calos eds.); and Current Protocols in Molecular Biology (F. M. Ausubel et al. eds., Wiley & Sons). Cell biology, protein chemistry, and antibody techniques can be found in Current Protocols in Protein Science (J. E. Colligan et al. eds., Wiley & Sons); Current Protocols in Cell Biology (J. S. Bonifacino et al., Wiley & Sons) and Current protocols in Immunology (J. E. Colligan et al. eds., Wiley & Sons.).

[0036] The association of telomerase expression with cancer is reviewed by Harley & Kim (Important Adv. Oncol. 57-67, 1996). General information on telomerase, telomere biology, and related techniques is provided in Telomerases, Telomeres and Cancer (G. Krupp & R. Parwaresch eds., Plenum Pub. Corp. 2002); Telomeres and Telomerase: Methods and Protocols (J. A. Double & M. J. Thompson eds., Humana Press 2002); and Telomerase, Aging and Disease (M. P. Mattson ed., Elsevier Science 2001).

[0037] Cross-Species Telomerase Epitopes

[0038] The source of cross-species TERT epitopes can be any species other than the one being immunized. Exemplary are human TERT (SEQ. ID NOs:1 and 2) in the mouse, and mouse TERT (SEQ. ID NOs:3 and 4) in the human. Other TERT species are also suitable for treating mammals, particularly if they are from another vertebrate or mammal. Further TERT species are listed in SEQ. ID NOs:5 to 10. Also suitable are consensus sequences, designed by compiling sequence information from other vertebrates, as exemplified in FIG. 10.

[0039] Other artificial sequences based on mammalian TERTs can also be used, in order to overcome self-tolerance and prime the cross-reactive response to autologous TERT. Such artificial sequences will typically share sequence identity across shared residues amongst the TERT family (FIG. 9), and one or more of the telomerase motifs described in U.S. Pat. No. 6,166,178, Nakamura et al. (Science 277:955, 1997), or Bryan et al. (Proc. Natl. Acad. Sci. USA;95:8479, 1998). Characteristic telomerase motifs have the following structures: Motif T W-R¹-X₇-R¹-R¹-R²-X-F-F-Y-X-T-E-X₈₋₉-R³-R³-R-R⁴-X₂-W Motif 1 X₃-R-X₂-P-K-X₃ Motif 2 X-R-X-I-X Motif A X₄-F-X₃-D-X₄-Y-D-X₂ Motif B′ Y-X₄-G-X₂-Q-G-X₃-S-X₈ Motif C X₆-D-D-X-L-X₃

[0040] where R′ is Leu or Ile; R² is Gln or Arg; R³ is Phe or Tyr; R⁴ is Lys or His, and X_(n) represents the number n of consecutive unspecified amino acids. Other naturally occurring TERTs from additional species can be obtained either by identifying ESTs in expression libraries according to the telomerase motifs, or by cloning them from mRNA libraries using suitable primers based on encoding regions conserved amongst TERT species (FIG. 10). Effectiveness of TERT homologs is best determined empirically, as illustrated in the Example section below.

[0041] A vaccine composition of this invention can be provided in the form of intact TERT protein or TERT fragments comprising at least one immunogenic epitope, typically in the range of 10, 20, 50, 100, 200, 500, or 1000 consecutive amino acids of the full-length sequence. Unless explicitly stated otherwise, reference in this disclosure to TERT protein, TERT peptide or TERT fragment refers interchangeably to portions of naturally occurring telomerase reverse transcriptase of any length. The peptide can be produced by artificial peptide synthesis, recombinant expression, or purification from natural sources.

[0042] Combinations of full length TERT or TERT fragments from 2, 3, or more different species are also contemplated, wherein one of the species is optionally the same as the species being treated, and the others provide a combination of xenogeneic epitopes from different sources. The TERT proteins may be combined in the same composition, or prepared as separate medicaments for immunization of the subject at the same or different times.

[0043] For use in immunogenic compositions, the TERT protein may or may not have telomerase activity when associated with telomerase RNA component. If telomerase activity is present, then it may impart increased telomerase activity near the injection site, as can be determined by TRAP assay (Kim et al., Science 266:2011, 1997).

[0044] It is often desirable to prevent telomerization of the injection site, by using a telomerase protein that is functionally inactive. This can be accomplished by using a single peptide or combination of separate peptides, none of which is of adequate length to retain telomerase activity. In a preferred embodiment, the composition comprises a mixture of overlapping or non-overlapping peptides of between about 10-50 (say, about 20-25) consecutive amino acids, spanning some or all of the full length of the naturally occurring TERT. In choosing peptides or TERT regions to be included in the composition, it is beneficial to select those parts of the molecule containing one or more T cell epitopes. Immunogenic epitopes in human TERT are known (Lev et al., Cancer Res. 62:3184, 2002). Databases and algorithms for identifying other T cell epitopes are available (Rammensee et al., Immunogenetics 50:213, 1999; Schirle et al., J. Immunol. Methods 257:1, 2001; Lu et al., Cancer Res. 60:5223, 2000).

[0045] Another way to produce a composition devoid of telomerase activity is to adapt the TERT by amino acid mutation or deletion to eliminate telomerase activity. Mutations in the motifs indicated above, such as removing or replacing the Asp residues in the A, B, or C motif, may reduce or abolish telomerase activity (U.S. Pat. No. 6,166,178). See also U.S. Pat. No. 6,337,200 for a description of suitable adaptations that eliminate telomerase activity while preserving useful epitopes. Adaptations effective in removing enzyme activity from the TERT gene of one species can usually be adapted in species orthologs or artificial homologs by making the same change at the corresponding position, determined by motif analysis or alignment of the two sequences.

[0046] Alternatively or in addition to TERT protein, the vaccine can contain a polynucleotide designed to cause the expression of TERT peptide after administration to the host. The encoded peptide can constitute any of the TERT orthologs, homologs, or fragments already described in any effective combination. The encoding region for the protein will typically be situated in the polynucleotide under control of a suitable tissue-specific or endogenous promoter. Suitable vector systems include naked DNA plasmids, liposomal compositions to enhance delivery, and viral vectors that cause transient expression. Exemplary are adenovirus vectors and vectors of the herpes family, especially in a non-replicative form.

[0047] This disclosure also provides new sequence data for Canis familiaris (dog) TERT, and for consensus and variant forms of TERT. The protein sequence and protein-encoding nucleotide sequences of the TERT family (either full-length, or in fragment form as already discussed) have many important applications. For example, they can be used for eliciting an immune response, increasing cell proliferation, determining TERT expression in cells and tissues, clinical diagnosis, and identification of telomerase inhibitors (U.S. Pat. Nos. 6,166,178, 6,261,836, 6,440,735, 6,444,650, and 6,475,789; PCT publications WO 99/27113 and WO 02/91999). Gene sequence upstream from the encoding region contains the TERT promoter, which also has several important applications, such as promoter-reporter, constructs, TERT-targeted vectors and oncolytic virus, and elimination of stem cells with undifferentiated phenotype (U.K. Patent GB 2321642; PCT publications WO 00/46355; WO 02/42468; and WO 02/42445).

[0048] This invention includes amongst its embodiments all of these applications of TERT, adapting the descriptions of the aforelisted disclosures mutatis mutandis with the novel sequence information listed herein. For the purpose of prosecution and interpretation of this disclosure in the U.S., the aforelisted patent publications are hereby incorporated herein by reference in their entirety.

[0049] Formulation

[0050] Skilled readers will already appreciate that telomerase protein and nucleic acid intended for use in clinical therapy of human or animal subjects will typically be formulated as a medicament that is both compatible with the nature of the active ingredient, and with the subject being treated. Dry powders can be used in certain contexts, but the active ingredient is often provided in the presence of a pharmaceutically compatible excipient. The entire composition will be produced under appropriate conditions, rendered sufficiently sterile and free of undesired contaminants in a manner that makes it suitable for administration to the subjects intended for treatment.

[0051] Formulation of pharmaceutical compounds will accord with contemporary standards and techniques. Medicaments intended for human administration will be prepared in adequately sterile conditions, in which the active ingredient(s) are combined with an isotonic solution or other pharmaceutical carrier appropriate for the recommended therapeutic use. Suitable formulations and techniques are generally described in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co, Easton Pa.). With respect to the use of nucleic acid vectors in therapeutic applications, the reader may wish to consult The Skin and Gene Therapy (U. R. Hengge & B. Volc-Platzer eds., Springer Verlag, 2000), or Gene Therapy (Advances in Pharmacology, Vol 40) (J. T. August, J. Coyle & M. W. Anders eds., Academic Press 1997). Aspects of the preparation and use of vaccines for the treatment of cancer can be found in such standard reference books as Cancer Vaccines and Immunotherapy, P. L. Stern et al. eds., Cambridge University Press 2000; DNA Vaccines: Methods and Protocols, D. B. Lowrie & R. Whalen eds., Humana Press 1999; Peptide-Based Cancer Vaccines, W. M. Cast, Landes Bioscience 2000; Therapeutic Vaccination Strategies, H. Hennekes et al. eds., Springer Verlag 2000; New Vaccine Technologies, R. W. Ellis ed., Landes Bioscience 2001; and Vaccine Adjuvants, D. T. O'Hagan ed., Humana Press 2002.

[0052] If appropriate, the immunogenic compositions of this invention can be combined with an adjuvant to potentiate the immune response. Classic adjuvants include oil emulsions, like complete Freund's adjuvant, and adherent surfaces such as alum. Adjuvants that recruit dendritic cells or help elicit cytotoxic T cells are especially useful, since telomerase is an antigen that is internal to the cell, and not usually expressed externally except in the context of the MHC. Other factors that otherwise boost the immune response or promote apoptosis or elimination of cancer cells can also be included in the composition. As illustrated below, particular factors of interest include but are not limited to IL-12, GM-CSF, IL-2, and MPL.

[0053] Multiple doses or different combinations of the immunogenic compositions of this invention can be packaged for distribution separately or together. Each composition or set of compositions can be accompanied with written instructions (in the form of promotional material or a package insert) regarding the use of the composition or combination in eliciting an immune response or the treatment of cancer.

[0054] Use for Immunization and Cancer Treatment

[0055] The manner in which the immunogenic compositions of this invention are used will depend on their formulation and the needs of the subject to be treated. If the subject is adequately primed, then a single administration may be sufficient, but multiple administrations (say, at least 2 or 4) are more usual. Separate doses can be given on a weekly or biweekly schedule, or as needed, until an adequate response is obtained, or on an ongoing basis. Depending on empirical optimization for treatment of particular conditions, nucleic acid vectors and protein vaccines of xenogeneic and isogenic TERT can be used in any effective combination. Combinations of current interest include multiple priming doses of xenogeneic TERT (or mixed xenogeneic and isogenic TERT). Use of adenovirus vectors in the priming stage may add to immunogenicity. The subsequent boosting or focusing phase can comprise multiple administrations of TERT (possibly isogenic TERT) as a DNA plasmid or peptide fragments. Initial trials may be conducted with 6 to 10 sequential administrations, and adjusted according to the findings obtained.

[0056] Effective doses of vaccines may fall within the range of 10 to 500 μg of TERT protein, or 1 to 500 μg of nucleic acid, depending on size of the subject, activity of the promoter and other factors. Suitable subjects include mammals of any kind, including research animals, livestock, pets, and human or non-human primates. Included are subjects that have (or are suspected of having) cancer or any other TERT-associated condition, and unaffected controls. A list of cancers suitable for treatment may be found in U.S. Pat. No. 6,166,178.

[0057] Other agents can be included in the protocol as part of a combination treatment strategy. For example, Flt-3 Ligand (˜20 μg/kg) can be administered daily for a week or two in advance of each injection of TERT to mobilize dendritic cells and enhance the response (Evans et al., Vaccine 21:322, 2002; Disis et al., Blood 99:2845, 2002). IL-2 (Pomer et al., Urologe 34:215, 1995) and GM-CSF (Simmons et al., Prostate 39:291, 1999) are two examples of agents that can be injected systemically to potentiate the immunization effect. An agent that depletes regulatory T lymphocytes, such as ONTAK® (denileukin diftitox, a recombinant diphtheria toxin) can be administered to the subjects ˜4 days in advance of the first dose of the vaccine, or as appropriate to down-regulate T lymphocyte mediated suppression, and overcome tolerance to self-antigen.

[0058] Desirable outcomes of the use of the compositions and treatment methods of this invention include activation of the immune system, and (if the treated subject previously had a telomerase-associated disease) improvement in the subject's clinical status. From an immunological standpoint, a T cell response is especially desirable, which can be measured in a proliferation assay (e.g., ELISPOT assay; D. I. Stott, J. Immunoassay 21:273, 2000), a cytotoxicity test (FIG. 3), or a specific cytokine secretion assay (FIG. 4). To measure an anti-hTERT response, the target cells can be hTERT transduced cells. To measure an anti-tumor response, the target cells can be a cancer cell line of the same tumor type as the subject. A particularly sensitive test is to take PBMCs from the immunized subject, make dendritic cells from the adherent fraction by culturing with IL-4 and GM-CSF, and transfect the DCs to express isogenic TERT. An assay is then run to ask whether T cells in the non-adherent fraction will respond when the autologous TERT-presenting DCs are used as stimulator cells.

[0059] Clinical objectives include inhibition of tumor growth (measured by a suitable technique such as caliper calibration or MRI), tumor regression, improved survival rate, and improved quality of life. Ultimate choice of the treatment protocol, dose, and monitoring is the responsibility of the managing clinician.

[0060] The examples that follow are provided by way of further illustration, and are not meant to limit the claimed invention.

EXAMPLES

[0061] Materials and Methods

[0062] hTERT and mTERT plasmid DNA vectors were used in all experiments. Full-length hTERT coding sequence was cloned into a high expression vector, gWiZ™ (Gene Therapy Systems, San Diego, Calif.) under control of a modified CMV promoter. A gWiZ™ mTERT vector was constructed by inserting the full-length mTERT gene in the same vector. gWiz™ blank vector was purchased from Genetic Therapy Systems and used as a negative control.

[0063] AdhTERT is a replication deficient, E1 and E3 deleted, recombinant adenovirus 5 based vector containing a cassette encoding the human telomerase gene under the control of CAG promoter construct (cytomegalovirus enhancer, chicken β-actin promoter, and part of the 3′ untranslated region of rabbit β-globin gene). The AdhTERT virus was generated by COS-TPC method (references 1 & 2) using the Adenovirus Expression Vector Kit from Takara Biomedicals (Tokyo, Japan). Briefly, the 3419 bp hTERT fragment was cloned into Swal site in pAxC wt cosmid (Takara Biomedicals, Tokyo, Japan) and transfected into 293 cells. The desired recombinant adenovirus was generated by homologous recombination in 293 cells. After several rounds of plaque purification, the rAdhTERT viruses were amplified in 293 cells and purified by CsCl density gradient ultracentrifugation. Viral particle concentration was determined by measuring optical density at A₂₆₀ and the infectious titer was determined by standard plaque assay.

[0064] AdmTERT has the same adenoviral backbone as AdhTERT, but contained a cassette encoding the murine telomerase coding sequence under the control of the CAG promoter.

[0065] In vivo vaccination and electroporation: Mice were anesthetized and vaccinated intramuscularly into tibialis with 100 μg of gWiZ™/hTERT, gWiz™/mTERT, or gWizT™ empty plasmid DNA in 50 μL PBS or saline immediately following the injection, a needle was inserted into the tibialis muscle and the muscle was electroporated. The conditions for in vivo electroporation were 180V; 2 pulses/direction=4 pulses total; 20 msec per pulse; needle distance 0.5 cm; 1 sec between pulses.

[0066] Stimulation of mouse spleen-derived T cells and CTL-assay in vitro: Spleens were harvested under sterile conditions, and single cell suspensions were prepared. Following lysis of red blood cells, NK-cells were depleted using NK-specific antibodies and magnetic beads. The T cells were then incubated with irradiated stimulator cells in the presence of IL-2. After 5 days, a standard ⁵¹Cr-release assay was performed measuring ⁵¹Cr content in the supernatant of 4 hr cultures of T cells cultured with irradiated ⁵¹Cr-labeled targets. Specific lysis was determined as (experimental lysis minus spontaneous lysis)÷(maximum lysis-spontaneous lysis)×100%.

[0067] Cytokine production: Following the 5-day culture, T cells were activated with PMA/lonomycin for 2 h and Brefeldin A for 2 h. After staining the cells for intracellular cytokine expression, the cells were analyzed using a BD-Vantage™ counter.

[0068] Results

[0069]FIG. 1 shows that three vaccinations with dendritic cells (DCs) primed with an adenovirus hTERT expression vector causes a delay in the growth of B10.2 tumor cells. C57BU6 mice (n=7 in each group) were immunized three times with 1×10⁶ murine bone marrow derived DCs transduced with 200 MOI of AdhTERT, AdmTERT, Ad-Empty or saline, as indicated, at 10-day intervals. 5×10⁵ B10.2 fibrosarcoma cells were injected intradermally in the abdomen area 10 days after the last DC immunization. Tumor growth was monitored twice weekly. Tumor area was calculated as tumor length×width.

[0070] B10.2 tumor growth was delayed in mice vaccinated with DC/AdhTERT, DC/Adh/mTERT or DC/AdmTERT plus AdIL-12.

[0071]FIG. 2 shows that tumor rejection correlates in this experiment with the presence of CD8⁺ T cells producing IFN-γ. Mice were sacrificed when tumors reached a limit size. Splenocytes, depleted of NK cells, were restimulated with AdhTERT modified B10.2 cells in vitro for 5 days. Then the percentage of CD8⁺/IFN-γ⁺ T cells was determined by flow cytometry after staining with anti-CD8 and anti-IFN-γ.

[0072] It was found that the tumor free mice in DC/AdhTERT or DC/Adh/mTERT groups had a higher frequency of CD8⁺/IFN-γ⁺ T cells. Tumor-bearing mice in these two groups as well as mice in control group had low percent of CD8^(+/IFN-γ) ⁺ T cells.

[0073]FIG. 3 (Upper Panels) show that vaccination with human TERT expression vectors will impart a response that is cross-reactive to epitopes on mouse TERT. C57BU6 mice were immunized eight times intramuscularly at ten-day intervals with 100 μg hTERT or control plasmid DNA (empty), followed by electroporation (180V/0.5 cm/2 pulses). One week after the last vaccination, the spleens were harvested and NK-depleted T cell cultures were stimulated in vitro using AdhTERT modified, IFN-γ treated (10 ng/mL) B16F10 mouse melanoma cells.

[0074] After 5 days, a standard cytotoxic T cell mediated target killing ⁵¹Cr release assay (CTL) was performed. The upper panels show CTL activity from individual mice vaccinated with hTERT-DNA, or control (empty plasmid) DNA. Targets were B16F10 mouse melanoma tumor cells transduced with AdhTERT (Left) or unmodified parental line (Right). The results show that immunization with hTERT generates CTLs that are specific for the mouse TERT expressed endogenously by the B16F10 tumor.

[0075]FIG. 3 (Lower Panels) show a similar experiment in which mice were vaccinated once with AdhTERT, and 3 times with hTERT-DNA plasmid; or with control vectors. CTLs from the immunized mice lyse B10.2 mouse tumor cells (Left) or C57 mouse fibrosarcoma cells (Right), by virtue of the mouse TERT expressed and presented by these cells. The results show that immunization with human TERT imparts cytotoxic immunity against endogenously expressed antigen expressed by tumor cells of a variety of different tissue types.

[0076]FIG. 4 shows IFN-γ expression by T cells from mice vaccinated with hTERT vectors. Data from two experiments with different vaccination regimens are presented. In Panel A, groups of mice were immunized once with AdhTERT, followed by 3 times with gWiz™ hTERT DNA plasmid, or with corresponding control vectors. Spleen cells were then harvested, stimulated in vitro for 5 days, and analyzed by flow cytometry for T cell subtype and IFN-γ expression. The results show specific induction of cytokine-secreting T cell subsets in animals immunized with hTERT, but not control.

[0077] In Panel B, individual mice were immunized 8 times with hTERT-DNA plasmid, or with control plasmid plus MPL (adjuvant). The results show that repeated immunization elicits a very high level of IFN-γ expressing T cells, especially those of the CD8 positive (CTL) subset.

[0078]FIG. 5 shows that xenogeneic antigen followed by self antigen is better than self antigen alone in generating CTL response against self antigen. C57BU6 mice were immunized intramuscularly four times (at a 10-14 day interval) with 100 μg DNA followed by in vivo electroporation. Group 1 was injected 4 times with AdmTERT. Group 3 was injected two times of hTERT DNA followed by two times of mTERT DNA. Groups 4 and 5 were injected four times with control plasmid or saline respectively. Ten days after the fourth immunization, splenocytes from an animal in each group were harvested. After depletion of NK cells, the cells were stimulated in vitro by culturing with irradiated B16/AdmTERT at a 10:1 ratio for five days. Panel A shows CTL killing of unmodified ⁵¹Cr labeled C57 fibrosarcoma cells. Panel B shows IFN-γ expression in the T cell subsets obtained after culturing in vitro.

[0079] The combination human and mouse TERT DNA vaccination was clearly better than mouse TERT DNA alone in generating mTERT-specific CD8 positive CTL response expressing IFN-γ, and capable of lysing mouse tumor cells.

[0080]FIG. 6 shows CTL results of a similar experiment in which mice were immunized four times with mTERT DNA, or twice each with hTERT DNA followed by mTERT DNA. Again, the mice immunized with a combination of hTERT and mTERT showed more mTERT-specific CTLs. The level of killing is higher in this experiment because the target cells had been transduced with AdmTERT. This confirms that the killing of the tumor cells is mediated by TERT antigen specific CTLs.

[0081]FIG. 7 shows that immunizing with a combination of hTERT and mTERT leads to a specific CTL response against autologous antigen. C57BU6 mice were immunized intramuscularly for total of nine times (at 10-14 day intervals) with 100 μg DNA followed by electroporation, as indicated. Ten days after the ninth immunization, two mice from each group were harvested. Splenocytes (depleted of NK cells) were stimulated in vitro by culturing 5 days with irradiated B16/AdmTERT at 10:1 ratio. Then a standard ⁵¹Cr-release assay was performed to determine mTERT-specific killing (mean±SEM). Target T cells were C57 fibrosarcoma cells transduced with AdmTERT.

[0082] The results show that the optimal regiment is a multiple immunization with xenogeneic human TERT, followed by a multiple immunization with autologous mouse TERT.

[0083]FIG. 8 shows inhibition of tumor growth in mice immunized with AdhTERT. C57BU6 mice were immunized three times, at an interval of 10-14 days, with AdhTERT virus (1×10⁹ TCID₅₀ per injection) or control virus, either intradermally (ID) or intramuscularly (IM). Two weeks after the last immunization, mice were challenged with B16F10 melanoma cells (2×10⁴/mouse) subcutaneously. Tumor growth was monitored twice weekly, and tumor volume was calculated as (Length×Width×Height)÷2. Significant tumor growth delay was observed in mice receiving AdhTERT vaccination compared with mice receiving control virus. Data in the AdhTERT group (n=14; mean±SEM) are pooled from mice immunized with AdhTERT (IM, n=5), AdhTERT (ID, n=5), AdhTERT plus the adjuvant MPL-SE (ID, n=4). Data in the AdEmpty group (n=12; mean±SE) are pooled from mice treated with AdEmpty (IM, n=4), AdEmpty (ID, n=4), and AdEmpty plus MPL-SE (ID, n=4).

[0084] Animals immunized with xenogeneic hTERT (diamonds) resisted tumor growth by almost 3-fold, compared with untreated mice (triangles) or vector control (squares). The results were significant at the level of p<0.1 (AdhTERT vs. PBS); p<0.05 (AdhTERT vs. vector control); and p<0.01 (AdhTERT vs. both controls) using the one tailed Student's t test.

References

[0085] 1. Miyake S M, Makimura M, Kanagae Y, et al. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci USA 1996; 93:1320-1324.

[0086] 2. Fu S, Diesseroth A B. Use of cosmid adenoviral vector cloning system for the in vitro construction of recombinant adenoviral vectors. Hum Gene Ther 1997; 8: 1321-13.

[0087] 3. Steitz J, Bruck J, Steinbrink K, Enk A, Knop J and Tuting T. genetic immunization of mice with human tyrosinase-related protein2: implications for the immunotherapy of melanoma. Int. J cancer 2000, 86: 89-94.

[0088] 4. Fong L, Brockstedt D, Benike C, Breen J K, Strang G, Ruegg C L, and Engelman E G. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol. 2001, 167: 7150-7156.

[0089] 5. Hawkins W G, Gold J S, Blachere N E, Bowne W B, Hoos A, lewis J J and Houghton A N. Xenogeneic DNA immunization in melanoma models for minimal residual disease. J Sur. Res., 2001, 102:137-143.

[0090] 6. Alexander A N, Huelsmeyer M K, Vail D M, Kurzman I D, and MacEwen E G. Phase I/II clinical trial utilizing a tumor cell vaccine encoding xenogeneic Gp100 in canine patients with mestastatic melanoma: immunological and clinical outcome. 2002, Abstract Number 4158, AACR Meeting, San Francisco, Calif.

[0091] 7. Wolchok J D, Perales M -A, Houghton A N and Bergman P J. Of mice and men (and dogs). 2002, Abstract Number 218, American Society of Gene Therapy Meeting, Boston.

[0092] The compositions and procedures described in this disclosure can be effectively modified by routine optimization without departing from the spirit of the invention embodied in the claims that follow.

Sequence Data

[0093] TABLE 4 Sequences Listed in this Disclosure SEQ. Descriptive ID NO: Annotation Source 1 Homo sapiens GenBank Locus telomerase reverse NM 003210. See transcriptase (TERT) also Nakamura et mRNA sequence al., Science 277:955, 1997; and GenBank Locus AF015950 2 amino acid sequence 3 Mus musculus (mouse) GenBank Locus TERT cDNA AF051911 See also sequence International Patent Publication WO 99/27113 and GenBank Locus NM_009354 4 amino acid sequence 5 Mesocricetus auratus GenBank Locus (golden hamster) AF149012 TERT cDNA sequence 6 amino acid sequence 7 Rattus norvegicus GenBank Locus (rat) TERT AF247818 cDNA sequence See also GenBank Locus AJ488949 8 amino acid sequence 9 Canis familiaris (dog) This invention TERT genomic sequence (FIG. 9) 10 amino acid sequence This invention (FIG. 10) 11 Consensus TERT This invention encoding sequence (FIG. 9) 12 Consensus TERT protein This invention sequence in which (FIG. 10) unspecified positions can be any amino acid

[0094]

1 12 1 4015 DNA Homo sapiens 1 gcagcgctgc gtcctgctgc gcacgtggga agccctggcc ccggccaccc ccgcgatgcc 60 gcgcgctccc cgctgccgag ccgtgcgctc cctgctgcgc agccactacc gcgaggtgct 120 gccgctggcc acgttcgtgc ggcgcctggg gccccagggc tggcggctgg tgcagcgcgg 180 ggacccggcg gctttccgcg cgctggtggc ccagtgcctg gtgtgcgtgc cctgggacgc 240 acggccgccc cccgccgccc cctccttccg ccaggtgtcc tgcctgaagg agctggtggc 300 ccgagtgctg cagaggctgt gcgagcgcgg cgcgaagaac gtgctggcct tcggcttcgc 360 gctgctggac ggggcccgcg ggggcccccc cgaggccttc accaccagcg tgcgcagcta 420 cctgcccaac acggtgaccg acgcactgcg ggggagcggg gcgtgggggc tgctgctgcg 480 ccgcgtgggc gacgacgtgc tggttcacct gctggcacgc tgcgcgctct ttgtgctggt 540 ggctcccagc tgcgcctacc aggtgtgcgg gccgccgctg taccagctcg gcgctgccac 600 tcaggcccgg cccccgccac acgctagtgg accccgaagg cgtctgggat gcgaacgggc 660 ctggaaccat agcgtcaggg aggccggggt ccccctgggc ctgccagccc cgggtgcgag 720 gaggcgcggg ggcagtgcca gccgaagtct gccgttgccc aagaggccca ggcgtggcgc 780 tgcccctgag ccggagcgga cgcccgttgg gcaggggtcc tgggcccacc cgggcaggac 840 gcgtggaccg agtgaccgtg gtttctgtgt ggtgtcacct gccagacccg ccgaagaagc 900 cacctctttg gagggtgcgc tctctggcac gcgccactcc cacccatccg tgggccgcca 960 gcaccacgcg ggccccccat ccacatcgcg gccaccacgt ccctgggaca cgccttgtcc 1020 cccggtgtac gccgagacca agcacttcct ctactcctca ggcgacaagg agcagctgcg 1080 gccctccttc ctactcagct ctctgaggcc cagcctgact ggcgctcgga ggctcgtgga 1140 gaccatcttt ctgggttcca ggccctggat gccagggact ccccgcaggt tgccccgcct 1200 gccccagcgc tactggcaaa tgcggcccct gtttctggag ctgcttggga accacgcgca 1260 gtgcccctac ggggtgctcc tcaagacgca ctgcccgctg cgagctgcgg tcaccccagc 1320 agccggtgtc tgtgcccggg agaagcccca gggctctgtg gcggcccccg aggaggagga 1380 cacagacccc cgtcgcctgg tgcagctgct ccgccagcac agcagcccct ggcaggtgta 1440 cggcttcgtg cgggcctgcc tgcgccggct ggtgccccca ggcctctggg gctccaggca 1500 caacgaacgc cgcttcctca ggaacaccaa gaagttcatc tccctgggga agcatgccaa 1560 gctctcgctg caggagctga cgtggaagat gagcgtgcgg gactgcgctt ggctgcgcag 1620 gagcccaggg gttggctgtg ttccggccgc agagcaccgt ctgcgtgagg agatcctggc 1680 caagttcctg cactggctga tgagtgtgta cgtcgtcgag ctgctcaggt ctttctttta 1740 tgtcacggag accacgtttc aaaagaacag gctctttttc taccggaaga gtgtctggag 1800 caagttgcaa agcattggaa tcagacagca cttgaagagg gtgcagctgc gggagctgtc 1860 ggaagcagag gtcaggcagc atcgggaagc caggcccgcc ctgctgacgt ccagactccg 1920 cttcatcccc aagcctgacg ggctgcggcc gattgtgaac atggactacg tcgtgggagc 1980 cagaacgttc cgcagagaaa agagggccga gcgtctcacc tcgagggtga aggcactgtt 2040 cagcgtgctc aactacgagc gggcgcggcg ccccggcctc ctgggcgcct ctgtgctggg 2100 cctggacgat atccacaggg cctggcgcac cttcgtgctg cgtgtgcggg cccaggaccc 2160 gccgcctgag ctgtactttg tcaaggtgga tgtgacgggc gcgtacgaca ccatccccca 2220 ggacaggctc acggaggtca tcgccagcat catcaaaccc cagaacacgt actgcgtgcg 2280 tcggtatgcc gtggtccaga aggccgccca tgggcacgtc cgcaaggcct tcaagagcca 2340 cgtctctacc ttgacagacc tccagccgta catgcgacag ttcgtggctc acctgcagga 2400 gaccagcccg ctgagggatg ccgtcgtcat cgagcagagc tcctccctga atgaggccag 2460 cagtggcctc ttcgacgtct tcctacgctt catgtgccac cacgccgtgc gcatcagggg 2520 caagtcctac gtccagtgcc aggggatccc gcagggctcc atcctctcca cgctgctctg 2580 cagcctgtgc tacggcgaca tggagaacaa gctgtttgcg gggattcggc gggacgggct 2640 gctcctgcgt ttggtggatg atttcttgtt ggtgacacct cacctcaccc acgcgaaaac 2700 cttcctcagg accctggtcc gaggtgtccc tgagtatggc tgcgtggtga acttgcggaa 2760 gacagtggtg aacttccctg tagaagacga ggccctgggt ggcacggctt ttgttcagat 2820 gccggcccac ggcctattcc cctggtgcgg cctgctgctg gatacccgga ccctggaggt 2880 gcagagcgac tactccagct atgcccggac ctccatcaga gccagtctca ccttcaaccg 2940 cggcttcaag gctgggagga acatgcgtcg caaactcttt ggggtcttgc ggctgaagtg 3000 tcacagcctg tttctggatt tgcaggtgaa cagcctccag acggtgtgca ccaacatcta 3060 caagatcctc ctgctgcagg cgtacaggtt tcacgcatgt gtgctgcagc tcccatttca 3120 tcagcaagtt tggaagaacc ccacattttt cctgcgcgtc atctctgaca cggcctccct 3180 ctgctactcc atcctgaaag ccaagaacgc agggatgtcg ctgggggcca agggcgccgc 3240 cggccctctg ccctccgagg ccgtgcagtg gctgtgccac caagcattcc tgctcaagct 3300 gactcgacac cgtgtcacct acgtgccact cctggggtca ctcaggacag cccagacgca 3360 gctgagtcgg aagctcccgg ggacgacgct gactgccctg gaggccgcag ccaacccggc 3420 actgccctca gacttcaaga ccatcctgga ctgatggcca cccgcccaca gccaggccga 3480 gagcagacac cagcagccct gtcacgccgg gctctacgtc ccagggaggg aggggcggcc 3540 cacacccagg cccgcaccgc tgggagtctg aggcctgagt gagtgtttgg ccgaggcctg 3600 catgtccggc tgaaggctga gtgtccggct gaggcctgag cgagtgtcca gccaagggct 3660 gagtgtccag cacacctgcc gtcttcactt ccccacaggc tggcgctcgg ctccacccca 3720 gggccagctt ttcctcacca ggagcccggc ttccactccc cacataggaa tagtccatcc 3780 ccagattcgc cattgttcac ccctcgccct gccctccttt gccttccacc cccaccatcc 3840 aggtggagac cctgagaagg accctgggag ctctgggaat ttggagtgac caaaggtgtg 3900 ccctgtacac aggcgaggac cctgcacctg gatgggggtc cctgtgggtc aaattggggg 3960 gaggtgctgt gggagtaaaa tactgaatat atgagttttt cagttttgaa aaaaa 4015 2 1132 PRT Homo sapiens 2 Met Pro Arg Ala Pro Arg Cys Arg Ala Val Arg Ser Leu Leu Arg Ser 1 5 10 15 His Tyr Arg Glu Val Leu Pro Leu Ala Thr Phe Val Arg Arg Leu Gly 20 25 30 Pro Gln Gly Trp Arg Leu Val Gln Arg Gly Asp Pro Ala Ala Phe Arg 35 40 45 Ala Leu Val Ala Gln Cys Leu Val Cys Val Pro Trp Asp Ala Arg Pro 50 55 60 Pro Pro Ala Ala Pro Ser Phe Arg Gln Val Ser Cys Leu Lys Glu Leu 65 70 75 80 Val Ala Arg Val Leu Gln Arg Leu Cys Glu Arg Gly Ala Lys Asn Val 85 90 95 Leu Ala Phe Gly Phe Ala Leu Leu Asp Gly Ala Arg Gly Gly Pro Pro 100 105 110 Glu Ala Phe Thr Thr Ser Val Arg Ser Tyr Leu Pro Asn Thr Val Thr 115 120 125 Asp Ala Leu Arg Gly Ser Gly Ala Trp Gly Leu Leu Leu Arg Arg Val 130 135 140 Gly Asp Asp Val Leu Val His Leu Leu Ala Arg Cys Ala Leu Phe Val 145 150 155 160 Leu Val Ala Pro Ser Cys Ala Tyr Gln Val Cys Gly Pro Pro Leu Tyr 165 170 175 Gln Leu Gly Ala Ala Thr Gln Ala Arg Pro Pro Pro His Ala Ser Gly 180 185 190 Pro Arg Arg Arg Leu Gly Cys Glu Arg Ala Trp Asn His Ser Val Arg 195 200 205 Glu Ala Gly Val Pro Leu Gly Leu Pro Ala Pro Gly Ala Arg Arg Arg 210 215 220 Gly Gly Ser Ala Ser Arg Ser Leu Pro Leu Pro Lys Arg Pro Arg Arg 225 230 235 240 Gly Ala Ala Pro Glu Pro Glu Arg Thr Pro Val Gly Gln Gly Ser Trp 245 250 255 Ala His Pro Gly Arg Thr Arg Gly Pro Ser Asp Arg Gly Phe Cys Val 260 265 270 Val Ser Pro Ala Arg Pro Ala Glu Glu Ala Thr Ser Leu Glu Gly Ala 275 280 285 Leu Ser Gly Thr Arg His Ser His Pro Ser Val Gly Arg Gln His His 290 295 300 Ala Gly Pro Pro Ser Thr Ser Arg Pro Pro Arg Pro Trp Asp Thr Pro 305 310 315 320 Cys Pro Pro Val Tyr Ala Glu Thr Lys His Phe Leu Tyr Ser Ser Gly 325 330 335 Asp Lys Glu Gln Leu Arg Pro Ser Phe Leu Leu Ser Ser Leu Arg Pro 340 345 350 Ser Leu Thr Gly Ala Arg Arg Leu Val Glu Thr Ile Phe Leu Gly Ser 355 360 365 Arg Pro Trp Met Pro Gly Thr Pro Arg Arg Leu Pro Arg Leu Pro Gln 370 375 380 Arg Tyr Trp Gln Met Arg Pro Leu Phe Leu Glu Leu Leu Gly Asn His 385 390 395 400 Ala Gln Cys Pro Tyr Gly Val Leu Leu Lys Thr His Cys Pro Leu Arg 405 410 415 Ala Ala Val Thr Pro Ala Ala Gly Val Cys Ala Arg Glu Lys Pro Gln 420 425 430 Gly Ser Val Ala Ala Pro Glu Glu Glu Asp Thr Asp Pro Arg Arg Leu 435 440 445 Val Gln Leu Leu Arg Gln His Ser Ser Pro Trp Gln Val Tyr Gly Phe 450 455 460 Val Arg Ala Cys Leu Arg Arg Leu Val Pro Pro Gly Leu Trp Gly Ser 465 470 475 480 Arg His Asn Glu Arg Arg Phe Leu Arg Asn Thr Lys Lys Phe Ile Ser 485 490 495 Leu Gly Lys His Ala Lys Leu Ser Leu Gln Glu Leu Thr Trp Lys Met 500 505 510 Ser Val Arg Asp Cys Ala Trp Leu Arg Arg Ser Pro Gly Val Gly Cys 515 520 525 Val Pro Ala Ala Glu His Arg Leu Arg Glu Glu Ile Leu Ala Lys Phe 530 535 540 Leu His Trp Leu Met Ser Val Tyr Val Val Glu Leu Leu Arg Ser Phe 545 550 555 560 Phe Tyr Val Thr Glu Thr Thr Phe Gln Lys Asn Arg Leu Phe Phe Tyr 565 570 575 Arg Lys Ser Val Trp Ser Lys Leu Gln Ser Ile Gly Ile Arg Gln His 580 585 590 Leu Lys Arg Val Gln Leu Arg Glu Leu Ser Glu Ala Glu Val Arg Gln 595 600 605 His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile 610 615 620 Pro Lys Pro Asp Gly Leu Arg Pro Ile Val Asn Met Asp Tyr Val Val 625 630 635 640 Gly Ala Arg Thr Phe Arg Arg Glu Lys Arg Ala Glu Arg Leu Thr Ser 645 650 655 Arg Val Lys Ala Leu Phe Ser Val Leu Asn Tyr Glu Arg Ala Arg Arg 660 665 670 Pro Gly Leu Leu Gly Ala Ser Val Leu Gly Leu Asp Asp Ile His Arg 675 680 685 Ala Trp Arg Thr Phe Val Leu Arg Val Arg Ala Gln Asp Pro Pro Pro 690 695 700 Glu Leu Tyr Phe Val Lys Val Asp Val Thr Gly Ala Tyr Asp Thr Ile 705 710 715 720 Pro Gln Asp Arg Leu Thr Glu Val Ile Ala Ser Ile Ile Lys Pro Gln 725 730 735 Asn Thr Tyr Cys Val Arg Arg Tyr Ala Val Val Gln Lys Ala Ala His 740 745 750 Gly His Val Arg Lys Ala Phe Lys Ser His Val Ser Thr Leu Thr Asp 755 760 765 Leu Gln Pro Tyr Met Arg Gln Phe Val Ala His Leu Gln Glu Thr Ser 770 775 780 Pro Leu Arg Asp Ala Val Val Ile Glu Gln Ser Ser Ser Leu Asn Glu 785 790 795 800 Ala Ser Ser Gly Leu Phe Asp Val Phe Leu Arg Phe Met Cys His His 805 810 815 Ala Val Arg Ile Arg Gly Lys Ser Tyr Val Gln Cys Gln Gly Ile Pro 820 825 830 Gln Gly Ser Ile Leu Ser Thr Leu Leu Cys Ser Leu Cys Tyr Gly Asp 835 840 845 Met Glu Asn Lys Leu Phe Ala Gly Ile Arg Arg Asp Gly Leu Leu Leu 850 855 860 Arg Leu Val Asp Asp Phe Leu Leu Val Thr Pro His Leu Thr His Ala 865 870 875 880 Lys Thr Phe Leu Arg Thr Leu Val Arg Gly Val Pro Glu Tyr Gly Cys 885 890 895 Val Val Asn Leu Arg Lys Thr Val Val Asn Phe Pro Val Glu Asp Glu 900 905 910 Ala Leu Gly Gly Thr Ala Phe Val Gln Met Pro Ala His Gly Leu Phe 915 920 925 Pro Trp Cys Gly Leu Leu Leu Asp Thr Arg Thr Leu Glu Val Gln Ser 930 935 940 Asp Tyr Ser Ser Tyr Ala Arg Thr Ser Ile Arg Ala Ser Leu Thr Phe 945 950 955 960 Asn Arg Gly Phe Lys Ala Gly Arg Asn Met Arg Arg Lys Leu Phe Gly 965 970 975 Val Leu Arg Leu Lys Cys His Ser Leu Phe Leu Asp Leu Gln Val Asn 980 985 990 Ser Leu Gln Thr Val Cys Thr Asn Ile Tyr Lys Ile Leu Leu Leu Gln 995 1000 1005 Ala Tyr Arg Phe His Ala Cys Val Leu Gln Leu Pro Phe His Gln 1010 1015 1020 Gln Val Trp Lys Asn Pro Thr Phe Phe Leu Arg Val Ile Ser Asp 1025 1030 1035 Thr Ala Ser Leu Cys Tyr Ser Ile Leu Lys Ala Lys Asn Ala Gly 1040 1045 1050 Met Ser Leu Gly Ala Lys Gly Ala Ala Gly Pro Leu Pro Ser Glu 1055 1060 1065 Ala Val Gln Trp Leu Cys His Gln Ala Phe Leu Leu Lys Leu Thr 1070 1075 1080 Arg His Arg Val Thr Tyr Val Pro Leu Leu Gly Ser Leu Arg Thr 1085 1090 1095 Ala Gln Thr Gln Leu Ser Arg Lys Leu Pro Gly Thr Thr Leu Thr 1100 1105 1110 Ala Leu Glu Ala Ala Ala Asn Pro Ala Leu Pro Ser Asp Phe Lys 1115 1120 1125 Thr Ile Leu Asp 1130 3 3426 DNA Mus musculus 3 gtgggaggcc catcccggcc ttgagcacaa tgacccgcgc tcctcgttgc cccgcggtgc 60 gctctctgct gcgcagccga taccgggagg tgtggccgct ggcaaccttt gtgcggcgcc 120 tggggcccga gggcaggcgg cttgtgcaac ccggggaccc gaagatctac cgcactttgg 180 ttgcccaatg cctagtgtgc atgcactggg gctcacagcc tccacctgcc gacctttcct 240 tccaccaggt gtcatccctg aaagagctgg tggccagggt tgtgcagaga ctctgcgagc 300 gcaacgagag aaacgtgctg gcttttggct ttgagctgct taacgaggcc agaggcgggc 360 ctcccatggc cttcactagt agcgtgcgta gctacttgcc caacactgtt attgagaccc 420 tgcgtgtcag tggtgcatgg atgctactgt tgagccgagt gggcgacgac ctgctggtct 480 acctgctggc acactgtgct ctttatcttc tggtgccccc cagctgtgcc taccaggtgt 540 gtgggtctcc cctgtaccaa atttgtgcca ccacggatat ctggccctct gtgtccgcta 600 gttacaggcc cacccgaccc gtgggcagga atttcactaa ccttaggttc ttacaacaga 660 tcaagagcag tagtcgccag gaagcaccga aacccctggc cttgccatct cgaggtacaa 720 agaggcatct gagtctcacc agtacaagtg tgccttcagc taagaaggcc agatgctatc 780 ctgtcccgag agtggaggag ggaccccaca ggcaggtgct accaacccca tcaggcaaat 840 catgggtgcc aagtcctgct cggtcccccg aggtgcctac tgcagagaaa gatttgtctt 900 ctaaaggaaa ggtgtctgac ctgagtctct ctgggtcggt gtgctgtaaa cacaagccca 960 gctccacatc tctgctgtca ccaccccgcc aaaatgcctt tcagctcagg ccatttattg 1020 agaccagaca tttcctttac tccaggggag atggccaaga gcgtctaaac ccctcattcc 1080 tactcagcaa cctccagcct aacttgactg gggccaggag actggtggag atcatctttc 1140 tgggctcaag gcctaggaca tcaggaccac tctgcaggac acaccgtcta tcgcgtcgat 1200 actggcagat gcggcccctg ttccaacagc tgctggtgaa ccatgcagag tgccaatatg 1260 tcagactcct caggtcacat tgcaggtttc gaacagcaaa ccaacaggtg acagatgcct 1320 tgaacaccag cccaccgcac ctcatggatt tgctccgcct gcacagcagt ccctggcagg 1380 tatatggttt tcttcgggcc tgtctctgca aggtggtgtc tgctagtctc tggggtacca 1440 ggcacaatga gcgccgcttc tttaagaact taaagaagtt catctcgttg gggaaatacg 1500 gcaagctatc actgcaggaa ctgatgtgga agatgaaagt agaggattgc cactggctcc 1560 gcagcagccc ggggaaggac cgtgtccccg ctgcagagca ccgtctgagg gagaggatcc 1620 tggctacgtt cctgttctgg ctgatggaca catacgtggt acagctgctt aggtcattct 1680 tttacatcac agagagcaca ttccagaaga acaggctctt cttctaccgt aagagtgtgt 1740 ggagcaagct gcagagcatt ggagtcaggc aacaccttga gagagtgcgg ctacgggagc 1800 tgtcacaaga ggaggtcagg catcaccagg acacctggct agccatgccc atctgcagac 1860 tgcgcttcat ccccaagccc aacggcctgc ggcccattgt gaacatgagt tatagcatgg 1920 gtaccagagc tttgggcaga aggaagcagg cccagcattt cacccagcgt ctcaagactc 1980 tcttcagcat gctcaactat gagcggacaa aacatcctca ccttatgggg tcttctgtac 2040 tgggtatgaa tgacatctac aggacctggc gggcctttgt gctgcgtgtg cgtgctctgg 2100 accagacacc caggatgtac tttgttaagg cagatgtgac cggggcctat gatgccatcc 2160 cccagggtaa gctggtggag gttgttgcca atatgatcag gcactcggag agcacgtact 2220 gtatccgcca gtatgcagtg gtccggagag atagccaagg ccaagtccac aagtccttta 2280 ggagacaggt caccaccctc tctgacctcc agccatacat gggccagttc cttaagcatc 2340 tgcaggattc agatgccagt gcactgagga actccgttgt catcgagcag agcatctcta 2400 tgaatgagag cagcagcagc ctgtttgact tcttcctgca cttcctgcgt cacagtgtcg 2460 taaagattgg tgacaggtgc tatacgcagt gccagggcat cccccagggc tccagcctat 2520 ccaccctgct ctgcagtctg tgtttcggag acatggagaa caagctgttt gctgaggtgc 2580 agcgggatgg gttgctttta cgttttgttg atgactttct gttggtgacg cctcacttgg 2640 accaagcaaa aaccttcctc agcaccctgg tccatggcgt tcctgagtat gggtgcatga 2700 taaacttgca gaagacagtg gtgaacttcc ctgtggagcc tggtaccctg ggtggtgcag 2760 ctccatacca gctgcctgct cactgcctgt ttccctggtg tggcttgctg ctggacactc 2820 agactttgga ggtgttctgt gactactcag gttatgccca gacctcaatt aagacgagcc 2880 tcaccttcca gagtgtcttc aaagctggga agaccatgcg gaacaagctc ctgtcggtct 2940 tgcggttgaa gtgtcacggt ctatttctag acttgcaggt gaacagcctc cagacagtct 3000 gcatcaatat atacaagatc ttcctgcttc aggcctacag gttccatgca tgtgtgattc 3060 agcttccctt tgaccagcgt gttaggaaga acctcacatt ctttctgggc atcatctcca 3120 gccaagcatc ctgctgctat gctatcctga aggtcaagaa tccaggaatg acactaaagg 3180 cctctggctc ctttcctcct gaagccgcac attggctctg ctaccaggcc ttcctgctca 3240 agctggctgc tcattctgtc atctacaaat gtctcctggg acctctgagg acagcccaaa 3300 aactgctgtg ccggaagctc ccagaggcga caatgaccat ccttaaagct gcagctgacc 3360 cagccctaag cacagacttt cagaccattt tggactaacc ctgtctcctt ccgctagatg 3420 aacatg 3426 4 1122 PRT Mus musculus 4 Met Thr Arg Ala Pro Arg Cys Pro Ala Val Arg Ser Leu Leu Arg Ser 1 5 10 15 Arg Tyr Arg Glu Val Trp Pro Leu Ala Thr Phe Val Arg Arg Leu Gly 20 25 30 Pro Glu Gly Arg Arg Leu Val Gln Pro Gly Asp Pro Lys Ile Tyr Arg 35 40 45 Thr Leu Val Ala Gln Cys Leu Val Cys Met His Trp Gly Ser Gln Pro 50 55 60 Pro Pro Ala Asp Leu Ser Phe His Gln Val Ser Ser Leu Lys Glu Leu 65 70 75 80 Val Ala Arg Val Val Gln Arg Leu Cys Glu Arg Asn Glu Arg Asn Val 85 90 95 Leu Ala Phe Gly Phe Glu Leu Leu Asn Glu Ala Arg Gly Gly Pro Pro 100 105 110 Met Ala Phe Thr Ser Ser Val Arg Ser Tyr Leu Pro Asn Thr Val Ile 115 120 125 Glu Thr Leu Arg Val Ser Gly Ala Trp Met Leu Leu Leu Ser Arg Val 130 135 140 Gly Asp Asp Leu Leu Val Tyr Leu Leu Ala His Cys Ala Leu Tyr Leu 145 150 155 160 Leu Val Pro Pro Ser Cys Ala Tyr Gln Val Cys Gly Ser Pro Leu Tyr 165 170 175 Gln Ile Cys Ala Thr Thr Asp Ile Trp Pro Ser Val Ser Ala Ser Tyr 180 185 190 Arg Pro Thr Arg Pro Val Gly Arg Asn Phe Thr Asn Leu Arg Phe Leu 195 200 205 Gln Gln Ile Lys Ser Ser Ser Arg Gln Glu Ala Pro Lys Pro Leu Ala 210 215 220 Leu Pro Ser Arg Gly Thr Lys Arg His Leu Ser Leu Thr Ser Thr Ser 225 230 235 240 Val Pro Ser Ala Lys Lys Ala Arg Cys Tyr Pro Val Pro Arg Val Glu 245 250 255 Glu Gly Pro His Arg Gln Val Leu Pro Thr Pro Ser Gly Lys Ser Trp 260 265 270 Val Pro Ser Pro Ala Arg Ser Pro Glu Val Pro Thr Ala Glu Lys Asp 275 280 285 Leu Ser Ser Lys Gly Lys Val Ser Asp Leu Ser Leu Ser Gly Ser Val 290 295 300 Cys Cys Lys His Lys Pro Ser Ser Thr Ser Leu Leu Ser Pro Pro Arg 305 310 315 320 Gln Asn Ala Phe Gln Leu Arg Pro Phe Ile Glu Thr Arg His Phe Leu 325 330 335 Tyr Ser Arg Gly Asp Gly Gln Glu Arg Leu Asn Pro Ser Phe Leu Leu 340 345 350 Ser Asn Leu Gln Pro Asn Leu Thr Gly Ala Arg Arg Leu Val Glu Ile 355 360 365 Ile Phe Leu Gly Ser Arg Pro Arg Thr Ser Gly Pro Leu Cys Arg Thr 370 375 380 His Arg Leu Ser Arg Arg Tyr Trp Gln Met Arg Pro Leu Phe Gln Gln 385 390 395 400 Leu Leu Val Asn His Ala Glu Cys Gln Tyr Val Arg Leu Leu Arg Ser 405 410 415 His Cys Arg Phe Arg Thr Ala Asn Gln Gln Val Thr Asp Ala Leu Asn 420 425 430 Thr Ser Pro Pro His Leu Met Asp Leu Leu Arg Leu His Ser Ser Pro 435 440 445 Trp Gln Val Tyr Gly Phe Leu Arg Ala Cys Leu Cys Lys Val Val Ser 450 455 460 Ala Ser Leu Trp Gly Thr Arg His Asn Glu Arg Arg Phe Phe Lys Asn 465 470 475 480 Leu Lys Lys Phe Ile Ser Leu Gly Lys Tyr Gly Lys Leu Ser Leu Gln 485 490 495 Glu Leu Met Trp Lys Met Lys Val Glu Asp Cys His Trp Leu Arg Ser 500 505 510 Ser Pro Gly Lys Asp Arg Val Pro Ala Ala Glu His Arg Leu Arg Glu 515 520 525 Arg Ile Leu Ala Thr Phe Leu Phe Trp Leu Met Asp Thr Tyr Val Val 530 535 540 Gln Leu Leu Arg Ser Phe Phe Tyr Ile Thr Glu Ser Thr Phe Gln Lys 545 550 555 560 Asn Arg Leu Phe Phe Tyr Arg Lys Ser Val Trp Ser Lys Leu Gln Ser 565 570 575 Ile Gly Val Arg Gln His Leu Glu Arg Val Arg Leu Arg Glu Leu Ser 580 585 590 Gln Glu Glu Val Arg His His Gln Asp Thr Trp Leu Ala Met Pro Ile 595 600 605 Cys Arg Leu Arg Phe Ile Pro Lys Pro Asn Gly Leu Arg Pro Ile Val 610 615 620 Asn Met Ser Tyr Ser Met Gly Thr Arg Ala Leu Gly Arg Arg Lys Gln 625 630 635 640 Ala Gln His Phe Thr Gln Arg Leu Lys Thr Leu Phe Ser Met Leu Asn 645 650 655 Tyr Glu Arg Thr Lys His Pro His Leu Met Gly Ser Ser Val Leu Gly 660 665 670 Met Asn Asp Ile Tyr Arg Thr Trp Arg Ala Phe Val Leu Arg Val Arg 675 680 685 Ala Leu Asp Gln Thr Pro Arg Met Tyr Phe Val Lys Ala Asp Val Thr 690 695 700 Gly Ala Tyr Asp Ala Ile Pro Gln Gly Lys Leu Val Glu Val Val Ala 705 710 715 720 Asn Met Ile Arg His Ser Glu Ser Thr Tyr Cys Ile Arg Gln Tyr Ala 725 730 735 Val Val Arg Arg Asp Ser Gln Gly Gln Val His Lys Ser Phe Arg Arg 740 745 750 Gln Val Thr Thr Leu Ser Asp Leu Gln Pro Tyr Met Gly Gln Phe Leu 755 760 765 Lys His Leu Gln Asp Ser Asp Ala Ser Ala Leu Arg Asn Ser Val Val 770 775 780 Ile Glu Gln Ser Ile Ser Met Asn Glu Ser Ser Ser Ser Leu Phe Asp 785 790 795 800 Phe Phe Leu His Phe Leu Arg His Ser Val Val Lys Ile Gly Asp Arg 805 810 815 Cys Tyr Thr Gln Cys Gln Gly Ile Pro Gln Gly Ser Ser Leu Ser Thr 820 825 830 Leu Leu Cys Ser Leu Cys Phe Gly Asp Met Glu Asn Lys Leu Phe Ala 835 840 845 Glu Val Gln Arg Asp Gly Leu Leu Leu Arg Phe Val Asp Asp Phe Leu 850 855 860 Leu Val Thr Pro His Leu Asp Gln Ala Lys Thr Phe Leu Ser Thr Leu 865 870 875 880 Val His Gly Val Pro Glu Tyr Gly Cys Met Ile Asn Leu Gln Lys Thr 885 890 895 Val Val Asn Phe Pro Val Glu Pro Gly Thr Leu Gly Gly Ala Ala Pro 900 905 910 Tyr Gln Leu Pro Ala His Cys Leu Phe Pro Trp Cys Gly Leu Leu Leu 915 920 925 Asp Thr Gln Thr Leu Glu Val Phe Cys Asp Tyr Ser Gly Tyr Ala Gln 930 935 940 Thr Ser Ile Lys Thr Ser Leu Thr Phe Gln Ser Val Phe Lys Ala Gly 945 950 955 960 Lys Thr Met Arg Asn Lys Leu Leu Ser Val Leu Arg Leu Lys Cys His 965 970 975 Gly Leu Phe Leu Asp Leu Gln Val Asn Ser Leu Gln Thr Val Cys Ile 980 985 990 Asn Ile Tyr Lys Ile Phe Leu Leu Gln Ala Tyr Arg Phe His Ala Cys 995 1000 1005 Val Ile Gln Leu Pro Phe Asp Gln Arg Val Arg Lys Asn Leu Thr 1010 1015 1020 Phe Phe Leu Gly Ile Ile Ser Ser Gln Ala Ser Cys Cys Tyr Ala 1025 1030 1035 Ile Leu Lys Val Lys Asn Pro Gly Met Thr Leu Lys Ala Ser Gly 1040 1045 1050 Ser Phe Pro Pro Glu Ala Ala His Trp Leu Cys Tyr Gln Ala Phe 1055 1060 1065 Leu Leu Lys Leu Ala Ala His Ser Val Ile Tyr Lys Cys Leu Leu 1070 1075 1080 Gly Pro Leu Arg Thr Ala Gln Lys Leu Leu Cys Arg Lys Leu Pro 1085 1090 1095 Glu Ala Thr Met Thr Ile Leu Lys Ala Ala Ala Asp Pro Ala Leu 1100 1105 1110 Ser Thr Asp Phe Gln Thr Ile Leu Asp 1115 1120 5 4170 DNA Mesocricetus auratus 5 gggaggcccg gccggatctt gagcgcgatg ccccgcgcgc cccgttgccg ggccgtgcgc 60 gctctgctgc gcagtcaata ccgtcaggtg tggccgctgg caaccttcgt gcggcgcctg 120 ggacctgagg gcaggcagct tgtacaaccc ggggacccaa aggtcttccg cacgttggtg 180 gcccggtgcc tagtgtgtgt gccctgggac tcacaacctc cacctgctga cctttccttc 240 caccaggtgt catcactgaa ggagctggtg gccagggtcg tgcagagact ctgcgagcgc 300 ggcgagagga acgtgctgac ttttggcttc gcgctgctta acggagccca aggcggtcct 360 cccatgacat tcacaaccag cgtgcgcagc tacctgccca actcggtgac tgagtctctg 420 cgcgtcagtg gtgcttggat gcttctgctg aaccgagtgg gcgacgactt gctggtctac 480 ctgctggccc gctgtgcgct ttacctgctg gtgcccccga gctgtgccta ccaggtgtgc 540 ggctcacccc tgtaccaaat ctgtgccacc gcagaaacct ggccttctgt gtcccgcatc 600 tacaggccca cacgacccgt gggcagaaat tttactcatc ttggatccac acaccgggtc 660 aggaacagca gtcaccagga agcatggaaa cccccgccct tgccatctcg agaggcgaag 720 cggagtctaa gcatcaccaa tagaagtgtg cctccatcta agaaggccag gtgcgatctg 780 gccccgagac tggagaaggg accctacagg caggcagttc caaccccatc agacaaaaca 840 tgggtgccaa atcctgccaa gtcccatgca gtgcctatta gtagaactac caaggaagat 900 ttgtcttccg gggtgaaggc acctggcctg agtcgctctg ggtcagtgtg ctataaacac 960 aagcccagtt ccacatccct gcagtcacca ctgtgccaaa atgcctttca gctcagacca 1020 tatactgaga ccaaacgctt cctctactct agggaaggtg gccgagagag gctgaacccc 1080 tcgttcctac tcaacaacct gcagcccagc ttgactgggg ccaggagact ggtagagata 1140 ctctttctag gcatgagacc taggacatcg ggaccactct gtgggagacg ccgcctatcg 1200 aagcgctact ggcagatgcg gcccctattc cagcagttgc ttgtgaacca tgcgcggtgc 1260 ccgtatgtcc ggctcctcag gtcccattgc aggtttcgga ccgcagccca ccaggtggca 1320 ggtgccttga acaccaccag cccacagcgc ctcatgaatt tgctccgtct acacagcagt 1380 ccctggcagg tatatggctt tcttcaggcc tgtgtcggaa agctggtgcc tccgggtctc 1440 tggggttccc ggcacaacca gcgacgcttc tttaagaacg tgaagcggtt catctccttg 1500 gggaagtatg acaagctgtc gctgcaggag ctgacgtgga agatgaaagt tcaagactgc 1560 aggtggcttc gcagcagccc agggaacaac tgtgtcccgg ctgcagagca ccgcacgagg 1620 gaaaggatcc tggctgtgtt cttgttctgg ctgatggacg cgtacgtggt agagctgctt 1680 cggtcattct tttacgtcac agagaccact ttccagaaga accggctctt cttctaccga 1740 aagagcatgt ggagaaggct gcagagcatt ggagtcaggc atcaccttga gagagtgcgg 1800 ctacaagaac tgtctcaaga agaagtcagg cagcgccagg aggcctggcc agccatgccc 1860 atctgcagac tgcgtttcat ccccaagccc agtggtcttc ggcccattgt gaacatgagt 1920 tatatgggca ccagagcctt tgacaaaggg aagcaggctc agcatttcac ccagtgtctc 1980 aagactctgt tcagcgtgct caactatgaa ctgacaaaac atactaacct tctgggggca 2040 tctgtactgg gcctgaatga tatctacagg acctggcgga ccttcgtact gcgtgtgcgc 2100 actctggacc cagcacccag gatgtacttt gttaaggcag atgtgacagg ggcatatgat 2160 gccatccccc aggacaagct tgtggaggtt attgccaata tgatcagaca cccagacaac 2220 tcgtactgta tccaccaata tgcagtggtc caaagagata gacaaggcca aatccacaag 2280 tccttcagga gacaggtctc caccctctct gacctccagc cacacatggg ccagttcttg 2340 aagcatcttc aggactcaga caccagtgcg ctgaggaact ccgttgtcat tgagcagagc 2400 ttatctctga acgaggccag cagcagcctg ttcgacttct tcctgcgctt tgtgcgtaac 2460 agtgtcgtga agatcggtgg caggtgctat gtccagtgcc agggcatccc ccagggctcc 2520 agcctgtcca ccctgctctg cagtctgtgt ttcggggaca tggagaacaa gctgtttgct 2580 gaagtgcagc aggatgggct gcttttgcgt tttgttgatg actttctgtt ggtgacacct 2640 cacctggtcc aggcggaagc cttcctcagg gccctcgtcc gtggcatccc tgagtacggc 2700 tgcatgataa acttgcagaa gacagtggta aacttccctg tggacgctgg taccctggat 2760 ggcacagctc cacaccagct gcctgctcac tgcctgtttc cctggtgtgg cttactgctg 2820 gacactcaga ctctggaggt gctctgtgac tacactggtt atgcccggac ctcaattaag 2880 gccagcctca ccttccagcg caccttcaag gcggggagga acatgcgaca gaagctctta 2940 gctgttttgc ggttgaagtg tcacagtctg tttctagact tgcagatgaa tagccttcag 3000 acagtctgta tcaatgtgta caagatcttc ctgcttcagg cctacaggtt ccatgcgtgt 3060 gcgcttcagc ttccctttga ccaacatgtt agaaagaacc ccgcattctt tctgagcatc 3120 atctccaaca tagcatcctg ctgctactcc atcctgaagg tcaagaatgc aggaatgaca 3180 ctaaaggcca agggtgcctc tggctcattt cctcctgaag ctgcacgttg gctctgctac 3240 caagccttcc tgctcaagct ggctggtcat tctgtcacct acaagtgtct cctgggacct 3300 ctcaggacag cacaaaaaca gctgtgccgg aagctcccaa gggcaacaat ggccatcctt 3360 gagactgccg ctgacccagc cctaagcaca gactttcaga ccattttgga ctaacccctc 3420 cccttcagct ggatgaacat gggcattgta gcctcaccac tcctggatgc atgccacaag 3480 agggactgac ctgttgtgag gccagtttgc cctccaaaac atgtgccagg gctgtagtat 3540 gggggttgtc cctgtgccgt gtttcctgtg gtggacttga tttctttcct gatgcctccg 3600 gggaagcagc tcccacccct ctcggtggca gggatccact agccagtaac accagacaga 3660 ggagaagatg cctgggcact gggacagtgt gcacggatct gagatgcccg gccctgtgtc 3720 tcttcacatc taacccatgg agcctttccc aacggggtca cagtagaaag tgtttttggg 3780 gggcttacag ttttaaaggt ttagaatcta tgatcatcac ggtagggagc atggcagcaa 3840 ggaggcaggc atgtgtcttc tcacgcctaa ccgaggagcc ttttccaatg ggccagtggg 3900 gtcagaatgt ctcagagatg aaaacaggac tttgaactga tgtgggggtt tgaagatgtg 3960 tagtccccac agacccgtgt gttcaaatgc ttggcctatt ggaatgtcac tattaggagg 4020 tgtggcttgt tggaggaagt gtgtctgtca ctgtgaggac agggctttca ggtctcatat 4080 atgctcaaac tgtgcccaat acacagacga cttctgctgc tatgaataaa gatgtagaac 4140 tctaaaaaaa aaaaaaaaaa aaaaaaaaaa 4170 6 1128 PRT Mesocricetus auratus 6 Met Pro Arg Ala Pro Arg Cys Arg Ala Val Arg Ala Leu Leu Arg Ser 1 5 10 15 Gln Tyr Arg Gln Val Trp Pro Leu Ala Thr Phe Val Arg Arg Leu Gly 20 25 30 Pro Glu Gly Arg Gln Leu Val Gln Pro Gly Asp Pro Lys Val Phe Arg 35 40 45 Thr Leu Val Ala Arg Cys Leu Val Cys Val Pro Trp Asp Ser Gln Pro 50 55 60 Pro Pro Ala Asp Leu Ser Phe His Gln Val Ser Ser Leu Lys Glu Leu 65 70 75 80 Val Ala Arg Val Val Gln Arg Leu Cys Glu Arg Gly Glu Arg Asn Val 85 90 95 Leu Thr Phe Gly Phe Ala Leu Leu Asn Gly Ala Gln Gly Gly Pro Pro 100 105 110 Met Thr Phe Thr Thr Ser Val Arg Ser Tyr Leu Pro Asn Ser Val Thr 115 120 125 Glu Ser Leu Arg Val Ser Gly Ala Trp Met Leu Leu Leu Asn Arg Val 130 135 140 Gly Asp Asp Leu Leu Val Tyr Leu Leu Ala Arg Cys Ala Leu Tyr Leu 145 150 155 160 Leu Val Pro Pro Ser Cys Ala Tyr Gln Val Cys Gly Ser Pro Leu Tyr 165 170 175 Gln Ile Cys Ala Thr Ala Glu Thr Trp Pro Ser Val Ser Arg Ile Tyr 180 185 190 Arg Pro Thr Arg Pro Val Gly Arg Asn Phe Thr His Leu Gly Ser Thr 195 200 205 His Arg Val Arg Asn Ser Ser His Gln Glu Ala Trp Lys Pro Pro Pro 210 215 220 Leu Pro Ser Arg Glu Ala Lys Arg Ser Leu Ser Ile Thr Asn Arg Ser 225 230 235 240 Val Pro Pro Ser Lys Lys Ala Arg Cys Asp Leu Ala Pro Arg Leu Glu 245 250 255 Lys Gly Pro Tyr Arg Gln Ala Val Pro Thr Pro Ser Asp Lys Thr Trp 260 265 270 Val Pro Asn Pro Ala Lys Ser His Ala Val Pro Ile Ser Arg Thr Thr 275 280 285 Lys Glu Asp Leu Ser Ser Gly Val Lys Ala Pro Gly Leu Ser Arg Ser 290 295 300 Gly Ser Val Cys Tyr Lys His Lys Pro Ser Ser Thr Ser Leu Gln Ser 305 310 315 320 Pro Leu Cys Gln Asn Ala Phe Gln Leu Arg Pro Tyr Thr Glu Thr Lys 325 330 335 Arg Phe Leu Tyr Ser Arg Glu Gly Gly Arg Glu Arg Leu Asn Pro Ser 340 345 350 Phe Leu Leu Asn Asn Leu Gln Pro Ser Leu Thr Gly Ala Arg Arg Leu 355 360 365 Val Glu Ile Leu Phe Leu Gly Met Arg Pro Arg Thr Ser Gly Pro Leu 370 375 380 Cys Gly Arg Arg Arg Leu Ser Lys Arg Tyr Trp Gln Met Arg Pro Leu 385 390 395 400 Phe Gln Gln Leu Leu Val Asn His Ala Arg Cys Pro Tyr Val Arg Leu 405 410 415 Leu Arg Ser His Cys Arg Phe Arg Thr Ala Ala His Gln Val Ala Gly 420 425 430 Ala Leu Asn Thr Thr Ser Pro Gln Arg Leu Met Asn Leu Leu Arg Leu 435 440 445 His Ser Ser Pro Trp Gln Val Tyr Gly Phe Leu Gln Ala Cys Val Gly 450 455 460 Lys Leu Val Pro Pro Gly Leu Trp Gly Ser Arg His Asn Gln Arg Arg 465 470 475 480 Phe Phe Lys Asn Val Lys Arg Phe Ile Ser Leu Gly Lys Tyr Asp Lys 485 490 495 Leu Ser Leu Gln Glu Leu Thr Trp Lys Met Lys Val Gln Asp Cys Arg 500 505 510 Trp Leu Arg Ser Ser Pro Gly Asn Asn Cys Val Pro Ala Ala Glu His 515 520 525 Arg Thr Arg Glu Arg Ile Leu Ala Val Phe Leu Phe Trp Leu Met Asp 530 535 540 Ala Tyr Val Val Glu Leu Leu Arg Ser Phe Phe Tyr Val Thr Glu Thr 545 550 555 560 Thr Phe Gln Lys Asn Arg Leu Phe Phe Tyr Arg Lys Ser Met Trp Arg 565 570 575 Arg Leu Gln Ser Ile Gly Val Arg His His Leu Glu Arg Val Arg Leu 580 585 590 Gln Glu Leu Ser Gln Glu Glu Val Arg Gln Arg Gln Glu Ala Trp Pro 595 600 605 Ala Met Pro Ile Cys Arg Leu Arg Phe Ile Pro Lys Pro Ser Gly Leu 610 615 620 Arg Pro Ile Val Asn Met Ser Tyr Met Gly Thr Arg Ala Phe Asp Lys 625 630 635 640 Gly Lys Gln Ala Gln His Phe Thr Gln Cys Leu Lys Thr Leu Phe Ser 645 650 655 Val Leu Asn Tyr Glu Leu Thr Lys His Thr Asn Leu Leu Gly Ala Ser 660 665 670 Val Leu Gly Leu Asn Asp Ile Tyr Arg Thr Trp Arg Thr Phe Val Leu 675 680 685 Arg Val Arg Thr Leu Asp Pro Ala Pro Arg Met Tyr Phe Val Lys Ala 690 695 700 Asp Val Thr Gly Ala Tyr Asp Ala Ile Pro Gln Asp Lys Leu Val Glu 705 710 715 720 Val Ile Ala Asn Met Ile Arg His Pro Asp Asn Ser Tyr Cys Ile His 725 730 735 Gln Tyr Ala Val Val Gln Arg Asp Arg Gln Gly Gln Ile His Lys Ser 740 745 750 Phe Arg Arg Gln Val Ser Thr Leu Ser Asp Leu Gln Pro His Met Gly 755 760 765 Gln Phe Leu Lys His Leu Gln Asp Ser Asp Thr Ser Ala Leu Arg Asn 770 775 780 Ser Val Val Ile Glu Gln Ser Leu Ser Leu Asn Glu Ala Ser Ser Ser 785 790 795 800 Leu Phe Asp Phe Phe Leu Arg Phe Val Arg Asn Ser Val Val Lys Ile 805 810 815 Gly Gly Arg Cys Tyr Val Gln Cys Gln Gly Ile Pro Gln Gly Ser Ser 820 825 830 Leu Ser Thr Leu Leu Cys Ser Leu Cys Phe Gly Asp Met Glu Asn Lys 835 840 845 Leu Phe Ala Glu Val Gln Gln Asp Gly Leu Leu Leu Arg Phe Val Asp 850 855 860 Asp Phe Leu Leu Val Thr Pro His Leu Val Gln Ala Glu Ala Phe Leu 865 870 875 880 Arg Ala Leu Val Arg Gly Ile Pro Glu Tyr Gly Cys Met Ile Asn Leu 885 890 895 Gln Lys Thr Val Val Asn Phe Pro Val Asp Ala Gly Thr Leu Asp Gly 900 905 910 Thr Ala Pro His Gln Leu Pro Ala His Cys Leu Phe Pro Trp Cys Gly 915 920 925 Leu Leu Leu Asp Thr Gln Thr Leu Glu Val Leu Cys Asp Tyr Thr Gly 930 935 940 Tyr Ala Arg Thr Ser Ile Lys Ala Ser Leu Thr Phe Gln Arg Thr Phe 945 950 955 960 Lys Ala Gly Arg Asn Met Arg Gln Lys Leu Leu Ala Val Leu Arg Leu 965 970 975 Lys Cys His Ser Leu Phe Leu Asp Leu Gln Met Asn Ser Leu Gln Thr 980 985 990 Val Cys Ile Asn Val Tyr Lys Ile Phe Leu Leu Gln Ala Tyr Arg Phe 995 1000 1005 His Ala Cys Ala Leu Gln Leu Pro Phe Asp Gln His Val Arg Lys 1010 1015 1020 Asn Pro Ala Phe Phe Leu Ser Ile Ile Ser Asn Ile Ala Ser Cys 1025 1030 1035 Cys Tyr Ser Ile Leu Lys Val Lys Asn Ala Gly Met Thr Leu Lys 1040 1045 1050 Ala Lys Gly Ala Ser Gly Ser Phe Pro Pro Glu Ala Ala Arg Trp 1055 1060 1065 Leu Cys Tyr Gln Ala Phe Leu Leu Lys Leu Ala Gly His Ser Val 1070 1075 1080 Thr Tyr Lys Cys Leu Leu Gly Pro Leu Arg Thr Ala Gln Lys Gln 1085 1090 1095 Leu Cys Arg Lys Leu Pro Arg Ala Thr Met Ala Ile Leu Glu Thr 1100 1105 1110 Ala Ala Asp Pro Ala Leu Ser Thr Asp Phe Gln Thr Ile Leu Asp 1115 1120 1125 7 1758 DNA Rattus norvegicus 7 aggtcattct tttacatcac agagagcaca ttccagaaga acaggctctt cttctaccgt 60 aagagtgtgt ggagcaagct gcagagcatt ggagtcaggc aacaccttga gagagtgcgg 120 ctacgggagc tgtcacaaga ggaggtcagg catcaccagg acacctggct agccatgccc 180 atctgcagac tgcgcttcat ccccaagccc aacggcctgc ggcccattgt gaacatgagt 240 tatagcatgg gtaccagagc tttgggcaga aggaagcagg cccagcattt cacccagcgt 300 ctcaagactc tcttcagcat gctcaactat gagcggacaa aacatcctca ccttatgggg 360 tcttctgtac tgggtatgaa tgacatctac aggacctggc gggcctttgt gctgcgtgtg 420 cgtgctctgg accagacacc caggatgtac tttgttaagg cagatgtgac cggggcctat 480 gatgccatcc cccagggtaa gctggtggag gttgttgcca atatgatcag gcactcggag 540 agcacgtact gtatccgcca gtatgcagtg gtccggagag atagccaagg ccaagtccac 600 aagtccttta ggagacaggt caccaccctc tctgacctcc agccatacat gggccagttc 660 cttaagcatc tgcaggattc agatgccagt gcactgagga actccgttgt catcgagcag 720 agcatctcta tgaatgagag cagcagcagc ctgtttgact tcttcctgca cttcctgcgt 780 cacagtgtcg taaagattgg tgacaggtgc tatacgcagt gccagggcat cccccagggc 840 tccagcctat ccaccctgct ctgcagtctg tgtttcggag acatggagaa caagctgttt 900 gctgaggtgc agcgggatgg gttgctttta cgttttgttg atgactttct gttggtgacg 960 cctcacttgg accaagcaaa aaccttcctc agcaccctgg tccatggcgt tcctgagtat 1020 gggtgcatga taaacttgca gaagacagtg gtgaacttcc ctgtggagcc tggtaccctg 1080 ggtggtgcag ctccatacca gctgcctgct cactgcctgt ttccctggtg tggcttgctg 1140 ctggacactc agactttgga ggtgttctgt gactactcag gttatgccca gacctcaatt 1200 aagacgagcc tcaccttcca gagtgtcttc aaagctggga agaccatgcg gaacaagctc 1260 ctgtcggtct tgcggttgaa gtgtcacggt ctatttctag acttgcaggt gaacagcctc 1320 cagacagtct gcatcaatat atacaagatc ttcctgcttc aggcctacag gttccatgca 1380 tgtgtgattc agcttccctt tgaccagcgt gttaggaaga acctcacatt ctttctgggc 1440 atcatctcca gccaagcatc ctgctgctat gctatcctga aggtcaagaa tccaggaatg 1500 acactaaagg cctctggctc ctttcctcct gaagccgcac attggctctg ctaccaggcc 1560 ttcctgctca agctggctgc tcattctgtc atctacaaat gtctcctggg acctctgagg 1620 acagcccaaa aactgctgtg ccggaagctc ccagaggcga caatgaccat ccttaaagct 1680 gcagctgacc cagccctaag cacagacttt cagaccattt tggactaacc ctgtctcctt 1740 ccgctagatg aacatggc 1758 8 575 PRT Rattus norvegicus 8 Arg Ser Phe Phe Tyr Ile Thr Glu Ser Thr Phe Gln Lys Asn Arg Leu 1 5 10 15 Phe Phe Tyr Arg Lys Ser Val Trp Ser Lys Leu Gln Ser Ile Gly Val 20 25 30 Arg Gln His Leu Glu Arg Val Arg Leu Arg Glu Leu Ser Gln Glu Glu 35 40 45 Val Arg His His Gln Asp Thr Trp Leu Ala Met Pro Ile Cys Arg Leu 50 55 60 Arg Phe Ile Pro Lys Pro Asn Gly Leu Arg Pro Ile Val Asn Met Ser 65 70 75 80 Tyr Ser Met Gly Thr Arg Ala Leu Gly Arg Arg Lys Gln Ala Gln His 85 90 95 Phe Thr Gln Arg Leu Lys Thr Leu Phe Ser Met Leu Asn Tyr Glu Arg 100 105 110 Thr Lys His Pro His Leu Met Gly Ser Ser Val Leu Gly Met Asn Asp 115 120 125 Ile Tyr Arg Thr Trp Arg Ala Phe Val Leu Arg Val Arg Ala Leu Asp 130 135 140 Gln Thr Pro Arg Met Tyr Phe Val Lys Ala Asp Val Thr Gly Ala Tyr 145 150 155 160 Asp Ala Ile Pro Gln Gly Lys Leu Val Glu Val Val Ala Asn Met Ile 165 170 175 Arg His Ser Glu Ser Thr Tyr Cys Ile Arg Gln Tyr Ala Val Val Arg 180 185 190 Arg Asp Ser Gln Gly Gln Val His Lys Ser Phe Arg Arg Gln Val Thr 195 200 205 Thr Leu Ser Asp Leu Gln Pro Tyr Met Gly Gln Phe Leu Lys His Leu 210 215 220 Gln Asp Ser Asp Ala Ser Ala Leu Arg Asn Ser Val Val Ile Glu Gln 225 230 235 240 Ser Ile Ser Met Asn Glu Ser Ser Ser Ser Leu Phe Asp Phe Phe Leu 245 250 255 His Phe Leu Arg His Ser Val Val Lys Ile Gly Asp Arg Cys Tyr Thr 260 265 270 Gln Cys Gln Gly Ile Pro Gln Gly Ser Ser Leu Ser Thr Leu Leu Cys 275 280 285 Ser Leu Cys Phe Gly Asp Met Glu Asn Lys Leu Phe Ala Glu Val Gln 290 295 300 Arg Asp Gly Leu Leu Leu Arg Phe Val Asp Asp Phe Leu Leu Val Thr 305 310 315 320 Pro His Leu Asp Gln Ala Lys Thr Phe Leu Ser Thr Leu Val His Gly 325 330 335 Val Pro Glu Tyr Gly Cys Met Ile Asn Leu Gln Lys Thr Val Val Asn 340 345 350 Phe Pro Val Glu Pro Gly Thr Leu Gly Gly Ala Ala Pro Tyr Gln Leu 355 360 365 Pro Ala His Cys Leu Phe Pro Trp Cys Gly Leu Leu Leu Asp Thr Gln 370 375 380 Thr Leu Glu Val Phe Cys Asp Tyr Ser Gly Tyr Ala Gln Thr Ser Ile 385 390 395 400 Lys Thr Ser Leu Thr Phe Gln Ser Val Phe Lys Ala Gly Lys Thr Met 405 410 415 Arg Asn Lys Leu Leu Ser Val Leu Arg Leu Lys Cys His Gly Leu Phe 420 425 430 Leu Asp Leu Gln Val Asn Ser Leu Gln Thr Val Cys Ile Asn Ile Tyr 435 440 445 Lys Ile Phe Leu Leu Gln Ala Tyr Arg Phe His Ala Cys Val Ile Gln 450 455 460 Leu Pro Phe Asp Gln Arg Val Arg Lys Asn Leu Thr Phe Phe Leu Gly 465 470 475 480 Ile Ile Ser Ser Gln Ala Ser Cys Cys Tyr Ala Ile Leu Lys Val Lys 485 490 495 Asn Pro Gly Met Thr Leu Lys Ala Ser Gly Ser Phe Pro Pro Glu Ala 500 505 510 Ala His Trp Leu Cys Tyr Gln Ala Phe Leu Leu Lys Leu Ala Ala His 515 520 525 Ser Val Ile Tyr Lys Cys Leu Leu Gly Pro Leu Arg Thr Ala Gln Lys 530 535 540 Leu Leu Cys Arg Lys Leu Pro Glu Ala Thr Met Thr Ile Leu Lys Ala 545 550 555 560 Ala Ala Asp Pro Ala Leu Ser Thr Asp Phe Gln Thr Ile Leu Asp 565 570 575 9 2231 DNA Canis familiaris 9 atgccgcgag cgccccggtg ccgcgccgtg cgcgccctgc tgcggggccg ctaccgggag 60 gtgctgcccc tggccacctt cctgcggcgc ctggggcccc cgggccggct gctcgtgcgg 120 cgcggggacc cggcggcctt ccgcgcgctg gtggcgcagt gcctggtgtg cgtgccctgg 180 ggcgcgcggc cgccccccgc cgccccgtgc ttccgccagc tggctttcgg cttcgccctg 240 ctggacggag cgcgcggcgg gccccccgtg gccttcacga ccagcgtgcg cagctacctg 300 cccaacacgg taaccgagac cctgcgcggc agcggcgcct gggggctgct gctgcgccgc 360 gtgggcgacg atgtgctcac ccacctgctg gcgcgctgcg cgctctacct gctggtggct 420 ccgagctgcg cctaccaggt gtgcgggccg ccgtctacga cctctgcgcc cccgcctctc 480 tgccgctccc ggccccgctc cccgctcccc gctccccgct cggccggccg ggctcgggac 540 ctcagaccca cacgccaggc cagaactcgg ccagcgcggg gcagcccgga gcggtcctct 600 ggaagcgcca gccagtggcg gagcagacgg cgccacaggc cttcccaggc cacagctcct 660 gtagcaagcc gggtgtacac ctgccgggcg cttccccagc tggcctggga gggaggcccc 720 ccggactcgt ccaaccaccc cagcctggat acatctccgg ggccccaggg agtaccccat 780 gacccagcac accccgagac caaacgcttc ctctactgct cgggtggcag ggagcggctg 840 cgcccctcct tcctgctcag tgccctgccg cctaccctgg gggcccgcaa actcgtggag 900 accatctttc tgggctctgc gccccagaag ccaggggccg cccgcaggat gcgccgcctg 960 cctgcccgct actggcgaat gaggcccctg ttccaggagc tgcttgggaa ccacgcccgg 1020 tgcccctacc gtgcgctcct caggacccac tgcccgcttc gggccatggc cgctaaggag 1080 gggtctggca accaggcaca caggggagtg ggcatctgtc ccctggagag gccagtagca 1140 gccccccagg agcagacgga ctccacacgc ctggtacagc tcctccgaca gcacagcagc 1200 ccctggcagg tgtatgcctt cctgagggcc tgcctgtgct ggctggtgcc cactggactc 1260 tggggctcca ggcacaacca gcgccgcttc ttgaggaacg tgaagaagtt catctccctg 1320 ggaaagcacg ctaagctctc cctgcaggaa ctgacgtgga agatgaaggt gcgggactgc 1380 acctggctgc acgggaaccc aggtgaggag tgcagagtga gcaggtgcct ggttggccta 1440 caggaaggac caggctcaca gcccgagtgt ggtaggcccc tccctcccaa ccatccatct 1500 cggaacaccc cttcctctgt tgggccggca gcgactgccc tgcctgcctc tcagcccccc 1560 gactcccgtc acaaactagt ccccatcccc agaggctgcc gggctgtcca catctgctgc 1620 caggagtcat gagacatcac gaaatgagct cttggtggcg gccctcatcc ccttaccccg 1680 ggcacacatg gctcctcata ggctgtgcgc cacaactctt caatagtgtg cacctccgag 1740 aactgtcaga agcagaggtc aggagacacc gggaagccag acctgctctg ctgacctcca 1800 gactccgctt cctccccaag cctagtgggc tgcggccgat tgtgaatatg gactacatca 1860 tgggagccag aacattccac agagacaaga aggtccagca tctcacctca caactgaaga 1920 cactgttcag tgtcctgaac tatgagcggg cccggcgccc cagcctccta ggggcctcca 1980 tgctgggcat ggacgacatc cacagggcct ggcgcacctt tgtgctacgc atacgggccc 2040 agaatccggc accccagctg tactttgtca aggtggacgt gacgggggca tatgacgccc 2100 tccctcagga caggctggta gaggtgattg ccaatgtgat caggcctcag gaaagcacat 2160 actgcgtgcg ccactatgcc gtggtccaga ggactgcccg gggacacgtc cgcaaggcct 2220 tcaaaagaca c 2231 10 743 PRT Canis familiaris 10 Met Pro Arg Ala Pro Arg Cys Arg Ala Val Arg Ala Leu Leu Arg Gly 1 5 10 15 Arg Tyr Arg Glu Val Leu Pro Leu Ala Thr Phe Leu Arg Arg Leu Gly 20 25 30 Pro Pro Gly Arg Leu Leu Val Arg Arg Gly Asp Pro Ala Ala Phe Arg 35 40 45 Ala Leu Val Ala Gln Cys Leu Val Cys Val Pro Trp Gly Ala Arg Pro 50 55 60 Pro Pro Ala Ala Pro Cys Phe Arg Gln Leu Ala Phe Gly Phe Ala Leu 65 70 75 80 Leu Asp Gly Ala Arg Gly Gly Pro Pro Val Ala Phe Thr Thr Ser Val 85 90 95 Arg Ser Tyr Leu Pro Asn Thr Val Thr Glu Thr Leu Arg Gly Ser Gly 100 105 110 Ala Trp Gly Leu Leu Leu Arg Arg Val Gly Asp Asp Val Leu Thr His 115 120 125 Leu Leu Ala Arg Cys Ala Leu Tyr Leu Leu Val Ala Pro Ser Cys Ala 130 135 140 Tyr Gln Val Cys Gly Pro Pro Ser Thr Thr Ser Ala Pro Pro Pro Leu 145 150 155 160 Cys Arg Ser Arg Pro Arg Ser Pro Leu Pro Ala Pro Arg Ser Ala Gly 165 170 175 Arg Ala Arg Asp Leu Arg Pro Thr Arg Gln Ala Arg Thr Arg Pro Ala 180 185 190 Arg Gly Ser Pro Glu Arg Ser Ser Gly Ser Ala Ser Gln Trp Arg Ser 195 200 205 Arg Arg Arg His Arg Pro Ser Gln Ala Thr Ala Pro Val Ala Ser Arg 210 215 220 Val Tyr Thr Cys Arg Ala Leu Pro Gln Leu Ala Trp Glu Gly Gly Pro 225 230 235 240 Pro Asp Ser Ser Asn His Pro Ser Leu Asp Thr Ser Pro Gly Pro Gln 245 250 255 Gly Val Pro His Asp Pro Ala His Pro Glu Thr Lys Arg Phe Leu Tyr 260 265 270 Cys Ser Gly Gly Arg Glu Arg Leu Arg Pro Ser Phe Leu Leu Ser Ala 275 280 285 Leu Pro Pro Thr Leu Gly Ala Arg Lys Leu Val Glu Thr Ile Phe Leu 290 295 300 Gly Ser Ala Pro Gln Lys Pro Gly Ala Ala Arg Arg Met Arg Arg Leu 305 310 315 320 Pro Ala Arg Tyr Trp Arg Met Arg Pro Leu Phe Gln Glu Leu Leu Gly 325 330 335 Asn His Ala Arg Cys Pro Tyr Arg Ala Leu Leu Arg Thr His Cys Pro 340 345 350 Leu Arg Ala Met Ala Ala Lys Glu Gly Ser Gly Asn Gln Ala His Arg 355 360 365 Gly Val Gly Ile Cys Pro Leu Glu Arg Pro Val Ala Ala Pro Gln Glu 370 375 380 Gln Thr Asp Ser Thr Arg Leu Val Gln Leu Leu Arg Gln His Ser Ser 385 390 395 400 Pro Trp Gln Val Tyr Ala Phe Leu Arg Ala Cys Leu Cys Trp Leu Val 405 410 415 Pro Thr Gly Leu Trp Gly Ser Arg His Asn Gln Arg Arg Phe Leu Arg 420 425 430 Asn Val Lys Lys Phe Ile Ser Leu Gly Lys His Ala Lys Leu Ser Leu 435 440 445 Gln Glu Leu Thr Trp Lys Met Lys Val Arg Asp Cys Thr Trp Leu His 450 455 460 Gly Asn Pro Gly Glu Glu Cys Arg Val Ser Arg Cys Leu Val Gly Leu 465 470 475 480 Gln Glu Gly Pro Gly Ser Gln Pro Glu Cys Gly Arg Pro Leu Pro Pro 485 490 495 Asn His Pro Ser Glu His Pro Phe Leu Cys Trp Ala Gly Ser Asp Cys 500 505 510 Pro Ala Cys Leu Ser Ala Pro Arg Leu Pro Ser Gln Thr Ser Pro His 515 520 525 Pro Gln Arg Leu Pro Gly Cys Pro His Leu Leu Pro Gly Val Met Arg 530 535 540 His His Glu Met Ser Ser Trp Trp Arg Pro Ser Ser Pro Tyr Pro Gly 545 550 555 560 His Thr Trp Leu Leu Ile Gly Cys Ala Pro Gln Leu Phe Asn Ser Val 565 570 575 His Leu Arg Glu Leu Ser Glu Ala Glu Val Arg Arg His Arg Glu Ala 580 585 590 Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Leu Pro Lys Pro Ser 595 600 605 Gly Leu Arg Pro Ile Val Asn Met Asp Tyr Ile Met Gly Ala Arg Thr 610 615 620 Phe His Arg Asp Lys Lys Val Gln His Leu Thr Ser Gln Leu Lys Thr 625 630 635 640 Leu Phe Ser Val Leu Asn Tyr Glu Arg Ala Arg Arg Pro Ser Leu Leu 645 650 655 Gly Ala Ser Met Leu Gly Met Asp Asp Ile His Arg Ala Trp Arg Thr 660 665 670 Phe Val Leu Arg Ile Arg Ala Gln Asn Pro Ala Pro Gln Leu Tyr Phe 675 680 685 Val Lys Val Asp Val Thr Gly Ala Tyr Asp Ala Leu Pro Gln Asp Arg 690 695 700 Leu Val Glu Val Ile Ala Asn Val Ile Arg Pro Gln Glu Ser Thr Tyr 705 710 715 720 Cys Val Arg His Tyr Ala Val Val Gln Arg Thr Ala Arg Gly His Val 725 730 735 Arg Lys Ala Phe Lys Arg His 740 11 2855 DNA Homo sapiens 11 atgcccgcgc ccccgtgccg gccgtgcgcc ctgctgcgca gcctaccgga ggtggccgct 60 ggcaccttcg tgcggcgcct ggggcccagg gcggcgctgt gcaccgggga cccgggcttc 120 cgccgtggtg gcccagtgcc tgtgtgcgtg ccctgggcca cgccccccgc cgcctccttc 180 cccaggtgtc tctgaagagc tggtggccgg ttgcagagct ctgcgagcgc cggaaacgtg 240 ctggctttgg cttcgcgctg ctacgggccc gggcggcccc ctggccttca caccagcgtg 300 cgcagctacc tgcccaacac ggtacgagcc tgcggcaggg gctgggctct gctggccggt 360 gggcgacgac tgctggtcac ctgctggccg ctggcgctta ctgctggtgc ccagctggcc 420 taccaggtgt gcgggcccct gtaccatctg gcccccactg gccctcgcca gcccccgcct 480 gggataacgc gacgagtcca ggagcagaac cccggcctgc cactcgggcg aggggcggcc 540 atgaagtgtg cccaagagcc aggcgcccgg cggagggccc acaggcaggc ccccgcaacg 600 gtccaagtcg tccgggtgcc tccgaaagtc ttggaggctg ccgagtcctc tcgtggcaac 660 acagccgtcc acatcgcgtc accaccccaa gctcacccat acgagaccaa accttcctct 720 actccgaggt ggcgagcggc tgcccctctt cctactcagc cctgcgccac tgactggggc 780 cggagactgt ggagacatct ttctgggctc aggccggaca ggcccgcagg acccgcctcc 840 gctactggca atgcggcccc tgttccagag ctgcttggaa ccagccgtgc cctaggctcc 900 tcaggccatg cgttcgcgcg ccacaggtgc ggcctgacac ccccccgcct tgatgctccg 960 cgcacagcag ccctggcagg ttatggcttc tcgggcctgc tgcgctggtg cccggctctg 1020 gggtccaggc acaacagcgc cgcttcttag aactaagaag ttcatctcct ggggaagagc 1080 aagcttcctg caggactgac gtggaagatg aagtcggact gctggctcgc agagcccagg 1140 gagactgtgt ccggctgcag agcaccgcga ggagaggatc ctggctgttc ctgctggctg 1200 atgacctacg tggtagctgc taggtcattc ttttacgtca cagagaccac attccagaag 1260 aacaggctct tcttctaccg aagagtgtgt ggagcaagct gcagagcatt ggagtcaggc 1320 aacaccttga gagagtgcgg ctacgggagc tgtcacaaga agaggtcagg cacaccagga 1380 gcctggccag ccatgcccat ctgcagactg cgcttcatcc ccaagcccaa cggctgcggc 1440 ccattgtgaa catgagttat acatgggacc agagcttggc agagggaagc aggcccagca 1500 tttcacccag cgtctcaaga ctctgttcag cgtgctcaac tatgagcgga caaaacatcc 1560 taccttctgg gggctctgta ctgggcatga atgacatcta caggacctgg cggacctttg 1620 tgctgcgtgt gcggctctgg acccgcaccc aggatgtact ttgttaaggc agatgtgacg 1680 gggctatgat gccatccccc aggacaagct ggtggaggtt attgccaata tgatcaggca 1740 ccggagagca cgtactgtat ccgccagtat gcagtggtcc agagagatag ccaaggccaa 1800 gtccacaagt ccttcaggag acaggtccca ccctctctga cctccagcca tacatgggcc 1860 agttctaagc atctgcagga tcagaccagt gcctgaggaa ctccgttgtc atcgagcaga 1920 gctctcttga atgagcagca gcagcctgtt gacttcttcc tgccttctgc gtcacagtgt 1980 cgtaagatgg tgcaggtgct atcagtgcca gggcatcccc cagggctcca gccttccacc 2040 ctgctctgca gtctgtgttt cgggacatgg agaacaagct gtttgctgag gtgcagcggg 2100 atgggtgctt ttcgttttgt tgatgacttt ctgttggtga ccctcactgg ccagcaaaac 2160 cttcctcaga ccctggtcct ggcgtcctga gtatggtgca tgataaactt gcagaagaca 2220 gtggtgaact tccctgtgga ctggtaccct gggtggcagc tccaaccagc tgcctgctca 2280 ctgcctgttt ccctggtgtg gcttgctgct ggacactcag acttggaggt gtctgtgact 2340 actcggttat gcccgacctc aattaagcag cctcaccttc cagggcttca agctgggaga 2400 catgcgacaa gctctcggtc ttgcggttga agtgtcacgt cttttctaga cttgcaggtg 2460 aacagcctcc agacagtctg catcaatatt acaagatctt cctgcttcag gcctacaggt 2520 tccatgcatg tgtgttcagc ttccctttga ccagctgtta ggaagaaccc acattctttc 2580 tggcatcatc tccacagcat cctgctgcta catcctgaag gtcaagaatc aggaatgaca 2640 ctaaaggcct ctggctcttt cctcctgaag ccgcacattg gctctgctac cagccttcct 2700 gctcaagctg gctgtcattc tgtcactaca atgtctcctg ggacctctag gacagcccaa 2760 aaacgctgtg ccggaagctc ccagggcgac aatgaccatc cttagctgca gctgacccag 2820 ccctaagcac agactttcag accattttgg actaa 2855 12 1152 PRT Homo sapiens 12 Met Pro Arg Ala Pro Arg Cys Arg Ala Val Arg Ala Leu Leu Arg Ser 1 5 10 15 His Tyr Arg Glu Val Leu Pro Leu Ala Thr Phe Val Arg Arg Leu Gly 20 25 30 Pro Glu Gly Arg Arg Leu Val Gln Pro Gly Asp Pro Ala Ala Phe Arg 35 40 45 Ala Leu Val Ala Gln Cys Leu Val Cys Val Pro Trp Gly Ala Arg Pro 50 55 60 Pro Pro Ala Ala Pro Ser Phe His Gln Val Ser Ser Leu Lys Glu Leu 65 70 75 80 Val Ala Arg Val Val Gln Arg Leu Cys Glu Arg Gly Glu Arg Asn Val 85 90 95 Leu Ala Phe Gly Phe Ala Leu Leu Asp Gly Ala Arg Gly Gly Pro Pro 100 105 110 Met Ala Phe Thr Thr Ser Val Arg Ser Tyr Leu Pro Asn Thr Val Thr 115 120 125 Glu Thr Leu Arg Gly Ser Gly Ala Trp Gly Leu Leu Leu Arg Arg Val 130 135 140 Gly Asp Asp Leu Leu Val His Leu Leu Ala Arg Cys Ala Leu Tyr Leu 145 150 155 160 Leu Val Ala Pro Ser Cys Ala Tyr Gln Val Cys Gly Pro Pro Leu Tyr 165 170 175 Gln Ile Gly Ala Thr Thr Gln Ala Arg Pro Pro Pro His Ala Ser Gly 180 185 190 Arg Pro Arg Arg Pro Val Gly Arg Asn Phe Thr Asn Leu Gly Phe Cys 195 200 205 Glu Arg Ala Trp Asn His Ser Val Arg Glu Ala Gly Val Pro Leu Gly 210 215 220 Leu Pro Ser Pro Gly Ala Lys Arg Arg Gly Gly Ser Ala Ser Arg Ser 225 230 235 240 Leu Pro Leu Pro Lys Lys Ala Arg Arg Gly Ala Ala Pro Glu Pro Glu 245 250 255 Arg Thr Pro Val Gly Gln Gly Ser Trp Thr Pro Ser Gly Arg Thr Arg 260 265 270 Val Pro Ser Asp Ala Gly Ser Pro Val Val Ser Pro Ala Arg Pro Ala 275 280 285 Glu Glu Asp Leu Ser Ser Lys Gly Lys Val Ser Asp Leu Ser Leu Ser 290 295 300 Gly Ser Val Cys Cys Lys His Lys Pro Ser Ser Pro Pro Ser Leu Ser 305 310 315 320 Ser Pro Pro Arg Pro Asn Ala Phe Gln Leu Arg Pro Val Tyr Ala Glu 325 330 335 Thr Lys His Phe Leu Tyr Ser Ser Gly Gly Arg Glu Arg Leu Arg Pro 340 345 350 Ser Phe Leu Leu Ser Asn Leu Gln Pro Ser Leu Thr Gly Ala Arg Arg 355 360 365 Leu Val Glu Thr Ile Phe Leu Gly Ser Arg Pro Trp Thr Ser Gly Pro 370 375 380 Leu Cys Arg Thr His Arg Leu Ser Arg Arg Tyr Trp Gln Met Arg Pro 385 390 395 400 Leu Phe Gln Glu Leu Leu Gly Asn His Ala Arg Cys Pro Tyr Val Arg 405 410 415 Leu Leu Arg Ser His Cys Pro Leu Arg Ala Ala Ala Thr Pro Val Ala 420 425 430 Gly Ala Leu Asn Thr Ser Pro Pro Gln Gly Ser Val Ala Ala Pro Glu 435 440 445 Glu Val Ala Ala Pro Gln Glu Gln Thr Asp Ser Thr Arg Leu Met Gln 450 455 460 Leu Leu Arg Gln His Ser Ser Pro Trp Gln Val Tyr Gly Phe Leu Arg 465 470 475 480 Ala Cys Leu Cys Lys Leu Val Pro Pro Gly Leu Trp Gly Ser Arg His 485 490 495 Asn Glu Arg Arg Phe Leu Lys Asn Val Lys Lys Phe Ile Ser Leu Gly 500 505 510 Lys His Ala Lys Leu Ser Leu Gln Glu Leu Thr Trp Lys Met Lys Val 515 520 525 Arg Asp Cys Ala Trp Leu Arg Ser Ser Pro Gly Tyr Glu Ser Val Pro 530 535 540 Ala Ala Glu His Arg Leu Arg Glu Arg Ile Leu Ala Lys Glu His Pro 545 550 555 560 Phe Leu Phe Trp Leu Met Ser Val Tyr Val Val Glu Leu Leu Arg Ser 565 570 575 Phe Phe Tyr Ile Thr Glu Ser Thr Phe Gln Lys Asn Arg Leu Phe Phe 580 585 590 Tyr Arg Lys Ser Val Trp Ser Lys Leu Gln Ser Ile Gly Val Arg Gln 595 600 605 His Leu Glu Arg Val Arg Leu Arg Glu Leu Ser Gln Glu Glu Val Arg 610 615 620 Gln His Gln Glu Ala Trp Pro Ala Met Pro Ile Cys Arg Leu Arg Phe 625 630 635 640 Ile Pro Lys Pro Asn Gly Leu Arg Pro Ile Val Asn Met Ser Tyr Ser 645 650 655 Met Gly Thr Arg Ala Phe Gly Arg Arg Lys Gln Ala Gln His Phe Thr 660 665 670 Gln Arg Leu Lys Thr Leu Phe Ser Val Leu Asn Tyr Glu Arg Thr Lys 675 680 685 His Pro His Leu Leu Gly Ala Ser Val Leu Gly Met Asn Asp Ile Tyr 690 695 700 Arg Thr Trp Arg Thr Phe Val Leu Arg Val Arg Ala Leu Asp Pro Thr 705 710 715 720 Pro Arg Met Tyr Phe Val Lys Ala Asp Val Thr Gly Ala Tyr Asp Ala 725 730 735 Ile Pro Gln Asp Lys Leu Val Glu Val Ile Ala Asn Met Ile Arg His 740 745 750 Ser Glu Ser Thr Tyr Cys Ile Arg Gln Tyr Ala Val Val Gln Arg Asp 755 760 765 Ala Gln Gly Gln Val His Lys Ser Phe Arg Arg Gln Val Ser Thr Leu 770 775 780 Ser Asp Leu Gln Pro Tyr Met Gly Gln Phe Leu Lys His Leu Gln Asp 785 790 795 800 Ser Asp Ala Ser Ala Leu Arg Asn Ser Val Val Ile Glu Gln Ser Ile 805 810 815 Ser Leu Asn Glu Ala Ser Ser Ser Leu Phe Asp Phe Phe Leu Arg Phe 820 825 830 Leu Arg His Ser Val Val Lys Ile Gly Gly Arg Cys Tyr Val Gln Cys 835 840 845 Gln Gly Ile Pro Gln Gly Ser Ser Leu Ser Thr Leu Leu Cys Ser Leu 850 855 860 Cys Phe Gly Asp Met Glu Asn Lys Leu Phe Ala Glu Val Gln Arg Asp 865 870 875 880 Gly Leu Leu Leu Arg Phe Val Asp Asp Phe Leu Leu Val Thr Pro His 885 890 895 Leu Asp Gln Ala Lys Thr Phe Leu Ser Thr Leu Val Arg Gly Val Pro 900 905 910 Glu Tyr Gly Cys Met Ile Asn Leu Gln Lys Thr Val Val Asn Phe Pro 915 920 925 Val Glu Pro Gly Thr Leu Gly Gly Thr Ala Pro Tyr Gln Leu Pro Ala 930 935 940 His Cys Leu Phe Pro Trp Cys Gly Leu Leu Leu Asp Thr Gln Thr Leu 945 950 955 960 Glu Val Phe Cys Asp Tyr Ser Gly Tyr Ala Arg Thr Ser Ile Lys Ala 965 970 975 Ser Leu Thr Phe Gln Arg Val Phe Lys Ala Gly Lys Asn Met Arg Asn 980 985 990 Lys Leu Leu Ser Val Leu Arg Leu Lys Cys His Ser Leu Phe Leu Asp 995 1000 1005 Leu Gln Val Asn Ser Leu Gln Thr Val Cys Ile Asn Ile Tyr Lys 1010 1015 1020 Ile Phe Leu Leu Gln Ala Tyr Arg Phe His Ala Cys Val Ile Gln 1025 1030 1035 Leu Pro Phe Asp Gln Arg Val Arg Lys Asn Pro Thr Phe Phe Leu 1040 1045 1050 Gly Ile Ile Ser Ser Gln Ala Ser Cys Cys Tyr Ala Ile Leu Lys 1055 1060 1065 Val Lys Asn Ala Gly Met Thr Leu Lys Ala Lys Gly Ala Ala Gly 1070 1075 1080 Ser Phe Pro Pro Glu Ala Ala His Trp Leu Cys Tyr Gln Ala Phe 1085 1090 1095 Leu Leu Lys Leu Ala Ala His Ser Val Thr Tyr Lys Cys Leu Leu 1100 1105 1110 Gly Pro Leu Arg Thr Ala Gln Lys Gln Leu Cys Arg Lys Leu Pro 1115 1120 1125 Glu Ala Thr Met Thr Ile Leu Glu Ala Ala Ala Asp Pro Ala Leu 1130 1135 1140 Ser Thr Asp Phe Gln Thr Ile Leu Asp 1145 1150 

The invention claimed is:
 1. A method for eliciting an immune response in a mammalian subject that is specific for its own telomerase reverse transcriptase (TERT), comprising administering to the subject an immunogenic composition containing a protein with at least 20 consecutive amino acids of TERT of another mammalian species, or a nucleic acid encoding said protein.
 2. The method of claim 1, wherein the protein comprises at least 100 consecutive amino acids of TERT of the other mammalian species.
 3. The method of claim 1, comprising administering the protein or nucleic acid to the subject on at least four different occasions.
 4. The method of claim 1, further comprising subsequently administering a second composition containing a second protein with at least 20 consecutive amino acids of TERT of the same species as the subject, or a nucleic acid encoding said second protein.
 5. The method of claim 1, which elicits a cytotoxic T cell response.
 6. The method of claim 1, wherein the protein is full-length TERT.
 7. The method of claim 1, wherein the immunogenic composition increases telomerase activity in cells surrounding the site of administration.
 8. The method of claim 1, wherein the protein lacks telomerase activity when associated with telomerase RNA due to one or more changes in amino acid sequence.
 9. The method of claim 1, wherein the composition contains either: a plurality of different proteins, each comprising at least 20 consecutive amino acids of TERT from one or more mammalian species different from the mammalian subject to which the composition is administered, or one or more nucleic acids encoding said plurality of proteins.
 10. The method of claim 1, wherein the protein comprises at least 20 consecutive amino acids of any of SEQ. ID NOs:4, 6, 8, 10, and
 12. 11. The method of claim 1, wherein the composition contains an adenovirus expression vector encoding the protein.
 12. The method of claim 1, wherein the composition also contains a factor selected from IL-12, GM-CSF, IL-2 and MPL.
 13. An immunogenic composition formulated for human administration, comprising a protein containing at least 20 consecutive amino acids of telomerase reverse transcriptase (TERT) of a non-human mammal, or a nucleic acid encoding said protein, which upon administration to a human patient having a tumor (optionally with simultaneous or sequential administration of another TERT protein or TERT-encoding nucleic acid) elicits an immunological response against human TERT.
 14. The composition of claim 13, wherein the protein comprises at least 100 consecutive amino acids of said non-human mammalian TERT.
 15. A combination of pharmaceutical compositions formulated for human administration, comprising: a) a first composition comprising a protein of at least 20 consecutive amino acids of telomerase reverse transcriptase (TERT) of a non-human mammal, or a nucleic acid encoding said protein; and b) a second composition comprising a second protein of at least 20 consecutive amino acids of human TERT, or a nucleic acid encoding said second protein; wherein administration of the compositions simultaneously or sequentially to a human patient having a tumor elicits an immunological response against human TERT.
 16. The composition of claim 13, wherein the TERT protein of the non-human mammal is full-length TERT.
 17. The composition of claim 13, wherein the TERT protein of the non-human mammal has telomerase activity when associated with telomerase RNA component.
 18. The composition of claim 13, wherein the TERT protein of the non-human mammal lacks telomerase activity due to one or more changes in amino acid sequence.
 19. The composition of claim 13, either containing a plurality of different proteins, each comprising at least 20 consecutive amino acids of TERT from one or more non-human mammals, or containing one or more nucleic acids encoding said plurality of proteins.
 20. The composition of claim 13, wherein the TERT protein of the non-human mammal comprises at least 20 consecutive amino acids of any of SEQ. ID NOs:4, 6, 8, 10, and
 12. 21. The composition of claim 13, wherein the composition contains an adenovirus expression vector encoding the protein.
 22. The composition of claim 13, wherein the composition also contains a factor selected from IL-12, GM-CSF, IL-2, and MPL.
 23. The composition(s) of claim 13, packaged with information on its use for eliciting an immunological response against human TERT.
 24. The composition(s) of claim 13, packaged with information on its use for treating cancer. 